

# David W Johnson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/234912/publications.pdf>

Version: 2024-02-01

873  
papers

48,348  
citations

2322

98  
h-index

3261

185  
g-index

887  
all docs

887  
docs citations

887  
times ranked

41264  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
2	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2009, 361, 2019-2032.	27.0	2,110
3	The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. <i>Lancet</i> , The, 2011, 377, 2181-2192.	13.7	2,087
4	Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. <i>New England Journal of Medicine</i> , 2009, 360, 1395-1407.	27.0	1,781
5	Peritoneal Dialysis-Related Infections Recommendations: 2010 Update. <i>Peritoneal Dialysis International</i> , 2010, 30, 393-423.	2.3	770
6	A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis. <i>New England Journal of Medicine</i> , 2010, 363, 609-619.	27.0	767
7	ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment. <i>Peritoneal Dialysis International</i> , 2016, 36, 481-508.	2.3	745
8	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. <i>Lancet</i> , The, 2017, 390, 1888-1917.	13.7	662
9	Prevalence of depression in chronic kidney disease: systematic review and meta-analysis of observational studies. <i>Kidney International</i> , 2013, 84, 179-191.	5.2	565
10	Cost analysis of ongoing care of patients with end-stage renal disease: The impact of dialysis modality and dialysis access. <i>American Journal of Kidney Diseases</i> , 2002, 40, 611-622.	1.9	428
11	Oxidative stress, anti-oxidant therapies and chronic kidney disease. <i>Nephrology</i> , 2012, 17, 311-321.	1.6	387
12	Changes in the worldwide epidemiology of peritoneal dialysis. <i>Nature Reviews Nephrology</i> , 2017, 13, 90-103.	9.6	384
13	Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2008, 336, 645-651.	2.3	382
14	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 432.	7.4	376
15	The Current State of Peritoneal Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3238-3252.	6.1	366
16	Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 313.	7.4	329
17	Plant communities affect arbuscular mycorrhizal fungal diversity and community composition in grassland microcosms. <i>New Phytologist</i> , 2004, 161, 503-515.	7.3	324
18	Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. <i>BMJ</i> , The, 2021, 372, m4573.	6.0	322

#	ARTICLE	IF	CITATIONS
19	Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2010, 153, 23.	3.9	297
20	Relationship between Dialysis Modality and Mortality. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 155-163.	6.1	282
21	Assessment of Global Kidney Health Care Status. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1864.	7.4	282
22	Effects of Allopurinol on the Progression of Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2020, 382, 2504-2513.	27.0	281
23	Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. <i>Kidney International</i> , 2019, 95, 160-172.	5.2	277
24	ISPD Position Statement on Reducing the Risks of Peritoneal Dialysis-Related Infections. <i>Peritoneal Dialysis International</i> , 2011, 31, 614-630.	2.3	273
25	Synbiotics Easing Renal Failure by Improving Gut Microbiology (SYNERGY). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 223-231.	4.5	271
26	A Randomized Trial of Dietary Sodium Restriction in CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 2096-2103.	6.1	253
27	Erythropoietin protects against ischaemic acute renal injury. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 348-355.	0.7	251
28	ISPD Catheter-Related Infection Recommendations: 2017 Update. <i>Peritoneal Dialysis International</i> , 2017, 37, 141-154.	2.3	239
29	Cost of acute renal failure requiring dialysis in the intensive care unit: Clinical and resource implications of renal recovery*. <i>Critical Care Medicine</i> , 2003, 31, 449-455.	0.9	234
30	Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. <i>American Journal of Kidney Diseases</i> , 2016, 68, 444-454.	1.9	232
31	Molecular cell biology of androgen receptor signalling. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 813-827.	2.8	231
32	Clinical Practice Guidelines for Peritoneal Access. <i>Peritoneal Dialysis International</i> , 2010, 30, 424-429.	2.3	222
33	Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. <i>American Journal of Kidney Diseases</i> , 2017, 70, 464-475.	1.9	218
34	The effect of obesity on renal transplant outcomes. <i>Transplantation</i> , 2002, 74, 675-681.	1.0	217
35	Mercury Distribution Across 14 U.S. Forests. Part I: Spatial Patterns of Concentrations in Biomass, Litter, and Soils. <i>Environmental Science &amp; Technology</i> , 2011, 45, 3974-3981.	10.0	211
36	ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. <i>Peritoneal Dialysis International</i> , 2022, 42, 110-153.	2.3	209

#	ARTICLE	IF	CITATIONS
37	Recent Peritonitis Associates with Mortality among Patients Treated with Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2012, 23, 1398-1405.	6.1	198
38	Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 268-280.	5.2	198
39	Effects of Biocompatible versus Standard Fluid on Peritoneal Dialysis Outcomes. Journal of the American Society of Nephrology: JASN, 2012, 23, 1097-1107.	6.1	191
40	Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2014, 29, 406-413.	0.7	191
41	Microbiology and Outcomes of Peritonitis in Australian Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2011, 31, 651-662.	2.3	183
42	Obesity Is Associated with Worse Peritoneal Dialysis Outcomes in the Australia and New Zealand Patient Populations. Journal of the American Society of Nephrology: JASN, 2003, 14, 2894-2901.	6.1	182
43	Chronic kidney disease and measurement of albuminuria or proteinuria: a position statement. Medical Journal of Australia, 2012, 197, 224-225.	1.7	179
44	Peritoneal Dialysis-Related Peritonitis: Towards Improving Evidence, Practices, and Outcomes. American Journal of Kidney Diseases, 2014, 64, 278-289.	1.9	178
45	Corticosteroid Therapy in IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1108-1116.	6.1	163
46	Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney International, 2006, 69, 1806-1813.	5.2	162
47	Factors influencing patient choice of dialysis versus conservative care to treat end-stage kidney disease. Cmaj, 2012, 184, E277-E283.	2.0	162
48	Catheter-Related Interventions to Prevent Peritonitis in Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2004, 15, 2735-2746.	6.1	161
49	Higher Peritoneal Transport Status Is Associated with Higher Mortality and Technique Failure in the Australian and New Zealand Peritoneal Dialysis Patient Populations. Journal of the American Society of Nephrology: JASN, 2006, 17, 271-278.	6.1	159
50	International Society for Peritoneal Dialysis practice recommendations: Prescribing high-quality goal-directed peritoneal dialysis. Peritoneal Dialysis International, 2020, 40, 244-253.	2.3	159
51	The importance of individuals: intraspecific diversity of mycorrhizal plants and fungi in ecosystems. New Phytologist, 2012, 194, 614-628.	7.3	157
52	Prevalence and Correlates of Self-Reported Sexual Dysfunction in CKD: A Meta-analysis of Observational Studies. American Journal of Kidney Diseases, 2010, 56, 670-685.	1.9	155
53	Reducing major risk factors for chronic kidney disease. Kidney International Supplements, 2017, 7, 71-87.	14.2	155
54	Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney International, 2010, 77, 904-912.	5.2	154

#	ARTICLE	IF	CITATIONS
55	A randomized controlled trial of topical exit site mupirocin application in patients with tunneled, cuffed haemodialysis catheters. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1802-1807.	0.7	148
56	Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrologyâ€“Hemodialysis (SONG-HD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2017, 69, 97-107.	1.9	148
57	Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1598-1603.	0.7	146
58	Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. <i>Medical Journal of Australia</i> , 2005, 183, 138-141.	1.7	144
59	Erythropoiesisâ€“stimulating agent hyporesponsiveness (Review Article). <i>Nephrology</i> , 2007, 12, 321-330.	1.6	143
60	HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. <i>The Cochrane Library</i> , 2014, , CD007784.	2.8	141
61	A COMPARISON OF THE EFFECTS OF DIALYSIS AND RENAL TRANSPLANTATION ON THE SURVIVAL OF OLDER UREMIC PATIENTS. <i>Transplantation</i> , 2000, 69, 794-799.	1.0	138
62	Association Between Depression and Death in People With CKD: A Meta-analysis of Cohort Studies. <i>American Journal of Kidney Diseases</i> , 2013, 62, 493-505.	1.9	137
63	<scp>KHAâ€“CARI</scp> Guideline: Early chronic kidney disease: Detection, prevention and management. <i>Nephrology</i> , 2013, 18, 340-350.	1.6	137
64	Protein-bound Uremic Toxins, Inflammation and Oxidative Stress: A Cross-sectional Study in Stage 3â€“4 Chronic Kidney Disease. <i>Archives of Medical Research</i> , 2014, 45, 309-317.	3.3	137
65	Randomized, Controlled Trial of Topical Exit-Site Application of Honey (Medihoney) versus Mupirocin for the Prevention of Catheter-Associated Infections in Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 1456-1462.	6.1	135
66	Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 281-295.	5.2	135
67	Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. <i>Kidney International</i> , 2009, 76, 622-628.	5.2	134
68	Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials. <i>American Journal of Kidney Diseases</i> , 2016, 68, 691-702.	1.9	132
69	Chronic kidney disease and the global NCDs agenda. <i>BMJ Global Health</i> , 2017, 2, e000380.	4.7	132
70	Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. <i>BMJ: British Medical Journal</i> , 2019, 367, I5873.	2.3	131
71	Predictors of Decline of Residual Renal Function in New Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2003, 23, 276-283.	2.3	130
72	Randomized, Controlled Trial of Glucose-Sparing Peritoneal Dialysis in Diabetic Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1889-1900.	6.1	128

#	ARTICLE	IF	CITATIONS
73	Obesity is a Risk Factor for Peritonitis in the Australian and New Zealand Peritoneal Dialysis Patient Populations. <i>Peritoneal Dialysis International</i> , 2004, 24, 340-346.	2.3	125
74	Dietary and Fluid Restrictions in CKD: A Thematic Synthesis of Patient Views From Qualitative Studies. <i>American Journal of Kidney Diseases</i> , 2015, 65, 559-573.	1.9	124
75	ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part I – Assessment and Management of Various Cardiovascular Risk Factors. <i>Peritoneal Dialysis International</i> , 2015, 35, 379-387.	2.3	123
76	Global nephrology workforce: gaps and opportunities toward a sustainable kidney care system. <i>Kidney International Supplements</i> , 2018, 8, 52-63.	14.2	123
77	Review article: Hepatitis B and dialysis. <i>Nephrology</i> , 2010, 15, 137-145.	1.6	120
78	Peritoneal Dialysis-Related Infection Rates and Outcomes: Results From the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). <i>American Journal of Kidney Diseases</i> , 2020, 76, 42-53.	1.9	120
79	Distal tubular epithelial cells of the kidney: Potential support for proximal tubular cell survival after renal injury. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1551-1561.	2.8	116
80	Endovascular Proximal Forearm Arteriovenous Fistula for Hemodialysis Access: Results of the Prospective, Multicenter Novel Endovascular Access Trial (NEAT). <i>American Journal of Kidney Diseases</i> , 2017, 70, 486-497.	1.9	115
81	Antimicrobial agents to prevent peritonitis in peritoneal dialysis: A systematic review of randomized controlled trials. <i>American Journal of Kidney Diseases</i> , 2004, 44, 591-603.	1.9	113
82	Activation of ERK in renal fibrosis after unilateral ureteral obstruction: Modulation by antioxidants. <i>Kidney International</i> , 2005, 67, 931-943.	5.2	113
83	Cost-Effectiveness of Initiating Dialysis Early: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2011, 57, 707-715.	1.9	113
84	Length of Time on Peritoneal Dialysis and Encapsulating Peritoneal Sclerosis – Position Paper for ISPD: 2017 Update. <i>Peritoneal Dialysis International</i> , 2017, 37, 362-374.	2.3	113
85	Paracrine stimulation of human renal fibroblasts by proximal tubule cells <sup>1</sup> . <i>Kidney International</i> , 1998, 54, 747-757.	5.2	112
86	Associations of Dialysis Modality and Infectious Mortality in Incident Dialysis Patients in Australia and New Zealand. <i>American Journal of Kidney Diseases</i> , 2009, 53, 290-297.	1.9	112
87	Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: new developments and revised recommendations. <i>Medical Journal of Australia</i> , 2012, 197, 222-223.	1.7	112
88	Is Obesity a Favorable Prognostic Factor in Peritoneal Dialysis Patients?. <i>Peritoneal Dialysis International</i> , 2000, 20, 715-721.	2.3	109
89	Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendations. <i>Medical Journal of Australia</i> , 2007, 187, 459-463.	1.7	109
90	Free Mycophenolic Acid Should Be Monitored in Renal Transplant Recipients with Hypoalbuminemia. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 284-286.	2.0	108

#	ARTICLE	IF	CITATIONS
91	Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2015, 25, 860-865.	2.6	108
92	Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease. <i>Annals of Internal Medicine</i> , 2019, 171, 181.	3.9	108
93	Obesity is Associated with Worsening Cardiovascular Risk Factor Profiles and Proteinuria Progression in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 2710-2718.	4.7	107
94	The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS): Unifying Efforts to Inform Practice and Improve Global Outcomes in Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2016, 36, 297-307.	2.3	107
95	Human Neutrophil Clearance of Bacterial Pathogens Triggers Anti-Microbial $\gamma\delta$ T Cell Responses in Early Infection. <i>PLoS Pathogens</i> , 2011, 7, e1002040.	4.7	106
96	Prevalence and severity of oral disease in adults with chronic kidney disease: a systematic review of observational studies. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 364-375.	0.7	106
97	Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease?. <i>American Journal of Medicine</i> , 2001, 110, 198-204.	1.5	103
98	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1888.	7.4	103
99	Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. <i>Nephrology</i> , 2007, 12, 391-398.	1.6	102
100	Dialysis Modality Preference of Patients With CKD and Family Caregivers: A Discrete-Choice Study. <i>American Journal of Kidney Diseases</i> , 2012, 60, 102-111.	1.9	102
101	Patient and Caregiver Priorities for Outcomes in Peritoneal Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 74-83.	4.5	101
102	Herbs or natural substances as complementary therapies for chronic kidney disease: ideas for future studies. <i>Translational Research</i> , 2006, 147, 160-166.	2.3	99
103	Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. <i>British Journal of Clinical Pharmacology</i> , 2005, 59, 271-280.	2.4	97
104	Epidemiology of haemodialysis outcomes. <i>Nature Reviews Nephrology</i> , 2022, 18, 378-395.	9.6	96
105	Interleukin-1 $\beta$ induces human proximal tubule cell injury, $\alpha$ -smooth muscle actin expression and fibronectin production. <i>Kidney International</i> , 2002, 62, 31-40.	5.2	94
106	Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2827-2847.	0.7	94
107	The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4445-4453.	0.7	94
108	Multicenter Registry Analysis of Center Characteristics Associated with Technique Failure in Patients on Incident Peritoneal Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1090-1099.	4.5	94



#	ARTICLE	IF	CITATIONS
109	Pseudomonas Peritonitis in Australia. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 957-964.	4.5	92
110	Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70 Diseases, 2020, 75, 404-412.	1.9	92
111	The Use of Vaccines in Renal Failure. Clinical Pharmacokinetics, 1992, 22, 434-446.	3.5	91
112	Interleukin-1 $\beta$ stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor- $\beta$ -dependent mechanism. Translational Research, 2002, 140, 342-350.	2.3	91
113	Prevalence and Causes of Low Bone Density and Fractures in Kidney Transplant Patients*. Journal of Bone and Mineral Research, 2001, 16, 1863-1870.	2.8	89
114	Once- Versus Twice-Daily Tacrolimus. Drugs, 2011, 71, 1561-1577.	10.9	87
115	Pre-, Pro-, and Synbiotics: Do They Have a Role in Reducing Uremic Toxins? A Systematic Review and Meta-Analysis. International Journal of Nephrology, 2012, 2012, 1-20.	1.3	87
116	Fall-related risk factors and osteoporosis in women with rheumatoid arthritis. British Journal of Rheumatology, 2004, 43, 1267-1271.	2.3	86
117	The Perspectives of Adults Living With Peritoneal Dialysis: Thematic Synthesis of Qualitative Studies. American Journal of Kidney Diseases, 2013, 61, 873-888.	1.9	86
118	Association of Dialysis Modality and Cardiovascular Mortality in Incident Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1620-1628.	4.5	85
119	Culture-Negative Peritonitis in Peritoneal Dialysis Patients in Australia: Predictors, Treatment, and Outcomes in 435 Cases. American Journal of Kidney Diseases, 2010, 55, 690-697.	1.9	85
120	Biocompatible dialysis fluids for peritoneal dialysis. The Cochrane Library, 2014, , CD007554.	2.8	85
121	Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. American Journal of Kidney Diseases, 2018, 72, 188-197.	1.9	85
122	Fruit and Vegetable Intake and Mortality in Adults undergoing Maintenance Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 250-260.	4.5	85
123	Predictors of baseline peritoneal transport status in Australian and New Zealand peritoneal dialysis patients. American Journal of Kidney Diseases, 2004, 43, 492-501.	1.9	84
124	HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. , 2009, , CD007784.		84
125	Staphylococcus Aureus Peritonitis in Australian Peritoneal Dialysis Patients: Predictors, Treatment, and Outcomes in 503 Cases. Peritoneal Dialysis International, 2010, 30, 311-319.	2.3	84
126	Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation, 2010, 25, 1973-1979.	0.7	84



#	ARTICLE	IF	CITATIONS
127	Pure Red Cell Aplasia Induced by Erythropoiesis-Stimulating Agents. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 193-199.	4.5	83
128	Sexual Dysfunction in Women with ESRD Requiring Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 974-981.	4.5	82
129	Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas project. <i>Kidney International Supplements</i> , 2018, 8, 64-73.	14.2	82
130	The Initiating Dialysis Early and Late (Ideal) Study: Study Rationale and Design. <i>Peritoneal Dialysis International</i> , 2004, 24, 176-181.	2.3	81
131	Polymicrobial Peritonitis in Peritoneal Dialysis Patients in Australia: Predictors, Treatment, and Outcomes. <i>American Journal of Kidney Diseases</i> , 2010, 55, 121-131.	1.9	80
132	Renal expression of transforming growth factor- $\beta$ 2 inducible gene-h3 ( $\beta$ 2ig-h3) in normal and diabetic rats. <i>Kidney International</i> , 1998, 54, 1052-1062.	5.2	79
133	Impact of obesity on renal transplant outcomes. <i>Nephrology</i> , 2005, 10, 405-413.	1.6	78
134	Dietary interventions for adults with chronic kidney disease. <i>The Cochrane Library</i> , 2017, 2017, CD011998.	2.8	78
135	Medicinal herbal extracts – renal friend or foe? Part one: The toxicities of medicinal herbs. <i>Nephrology</i> , 2004, 9, 313-318.	1.6	77
136	Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 23-30.	9.1	76
137	Simple mass spectrometric differentiation of the n-3, n-6 and n-9 series of methylene interrupted polyenoic acids. <i>Biomedical &amp; Environmental Mass Spectrometry</i> , 1987, 14, 127-129.	1.6	75
138	Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1899-1907.	0.7	75
139	Prebiotic, Probiotic, and Synbiotic Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-analysis. , 2019, 29, 209-220.		75
140	How do plants regulate the function, community structure, and diversity of mycorrhizal fungi?. <i>Journal of Experimental Botany</i> , 2005, 56, 1751-1760.	4.8	74
141	A 4-year review of pediatric mental health emergencies in Alberta. <i>Canadian Journal of Emergency Medicine</i> , 2009, 11, 447-454.	1.1	74
142	Peritoneal dialysis practice in Australia and New Zealand: A call to action. <i>Nephrology</i> , 2011, 16, 19-29.	1.6	74
143	Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. <i>Peritoneal Dialysis International</i> , 2004, 24, 340-6.	2.3	74
144	Differences in Admission Rates of Children With Bronchiolitis by Pediatric and General Emergency Departments. <i>Pediatrics</i> , 2002, 110, e49-e49.	2.1	73

#	ARTICLE	IF	CITATIONS
145	The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. <i>Kidney International</i> , 2013, 84, 969-979.	5.2	73
146	Root traits predict decomposition across a landscape-scale grazing experiment. <i>New Phytologist</i> , 2014, 203, 851-862.	7.3	73
147	Research Priorities in CKD: Report of a National Workshop Conducted in Australia. <i>American Journal of Kidney Diseases</i> , 2015, 66, 212-222.	1.9	73
148	Early and Late Patient Outcomes in Urgent-Start Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2017, 37, 414-419.	2.3	73
149	An international Delphi survey helped develop consensus-based core outcome domains for trials in peritoneal dialysis. <i>Kidney International</i> , 2019, 96, 699-710.	5.2	73
150	A Randomized Controlled Trial of Coiled Versus Straight Swan-Neck Tenckhoff Catheters in Peritoneal Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2006, 48, 812-821.	1.9	71
151	Kidneys from patients with small renal tumours: a novel source of kidneys for transplantation. <i>BJU International</i> , 2008, 102, 188-193.	2.5	71
152	Duration of Hemodialysis following Peritoneal Dialysis Cessation in Australia and New Zealand: Proposal for a Standardized Definition of Technique Failure. <i>Peritoneal Dialysis International</i> , 2016, 36, 623-630.	2.3	71
153	Enterococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 116 cases. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1272-1278.	0.7	70
154	Establishing a Core Outcome Measure for Fatigue in Patients on Hemodialysis: A Standardized Outcomes in Nephrology Hemodialysis (SONG-HD) Consensus Workshop Report. <i>American Journal of Kidney Diseases</i> , 2018, 72, 104-112.	1.9	69
155	Contemporary clinical usage of LC/MS: Analysis of biologically important carboxylic acids. <i>Clinical Biochemistry</i> , 2005, 38, 351-361.	1.9	68
156	Automated and continuous ambulatory peritoneal dialysis have similar outcomes. <i>Kidney International</i> , 2008, 73, 480-488.	5.2	68
157	The impact of automated eGFR reporting and education on nephrology service referrals. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3845-3850.	0.7	68
158	Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3654-3661.	0.7	68
159	Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials. <i>American Journal of Kidney Diseases</i> , 2017, 70, 324-336.	1.9	68
160	Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. <i>American Heart Journal</i> , 2006, 151, 745-753.	2.7	67
161	Is the Declining Use of Long-Term Peritoneal Dialysis Justified by Outcome Data?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 1317-1328.	4.5	67
162	The emerging role of nuclear factor kappa B in renal cell carcinoma. <i>International Journal of Biochemistry and Cell Biology</i> , 2011, 43, 1537-1549.	2.8	67

#	ARTICLE	IF	CITATIONS
163	The Effects of Biocompatible Compared with Standard Peritoneal Dialysis Solutions on Peritonitis Microbiology, Treatment, and Outcomes: The <i>BALANZ</i> Trial. <i>Peritoneal Dialysis International</i> , 2012, 32, 497-506.	2.3	67
164	Standardised outcomes in nephrology “Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. <i>Trials</i> , 2015, 16, 364.	1.6	67
165	Coal microstructure and secondary mineralization: their effect on methane recovery. <i>Geological Society Special Publication</i> , 1996, 109, 165-179.	1.3	66
166	Compared with Younger Peritoneal Dialysis Patients, Elderly Patients have Similar Peritonitis-Free Survival and Lower Risk of Technique Failure, but Higher Risk of Peritonitis-Related Mortality. <i>Peritoneal Dialysis International</i> , 2011, 31, 663-671.	2.3	66
167	Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. <i>American Journal of Kidney Diseases</i> , 2018, 71, 814-821.	1.9	66
168	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 673-684.	4.5	66
169	Predictors of decline of residual renal function in new peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2003, 23, 276-83.	2.3	66
170	HMG CoA reductase inhibitors (statins) for dialysis patients. , 2009, , CD004289.		65
171	International consensus definitions of clinical trial outcomes for kidney failure: 2020. <i>Kidney International</i> , 2020, 98, 849-859.	5.2	65
172	Modification of cardiovascular risk in hemodialysis patients: An evidence-based review. <i>Hemodialysis International</i> , 2007, 11, 1-14.	0.9	63
173	Intradermal Versus Intramuscular Hepatitis B Vaccination in Hemodialysis Patients: A Prospective Open-Label Randomized Controlled Trial in Nonresponders to Primary Vaccination. <i>American Journal of Kidney Diseases</i> , 2009, 54, 95-103.	1.9	63
174	Relapsing and Recurrent Peritoneal Dialysis-Associated Peritonitis: A Multicenter Registry Study. <i>American Journal of Kidney Diseases</i> , 2011, 58, 429-436.	1.9	63
175	Predictors, treatment, and outcomes of non- <i>Pseudomonas</i> Gram-negative peritonitis. <i>Kidney International</i> , 2010, 78, 408-414.	5.2	62
176	A new simple and rapid LC-ESI-MS/MS method for quantification of plasma oxysterols as dimethylaminobutyrate esters. Its successful use for the diagnosis of Niemann-Pick type C disease. <i>Clinica Chimica Acta</i> , 2014, 437, 93-100.	1.1	62
177	Report of the Standardized Outcomes in Nephrology “Haemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure for Hemodialysis Vascular Access. <i>American Journal of Kidney Diseases</i> , 2018, 71, 690-700.	1.9	62
178	Peritoneal Dialysis Use and Practice Patterns: An International Survey Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 315-325.	1.9	62
179	A rapid screening procedure for cholesterol and dehydrocholesterol by electrospray ionization tandem mass spectrometry. <i>Journal of Lipid Research</i> , 2001, 42, 1699-1705.	4.2	62
180	The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. <i>American Journal of Kidney Diseases</i> , 2004, 43, 45-52.	1.9	61

#	ARTICLE	IF	CITATIONS
181	The impact of extended hours home hemodialysis and buttonhole cannulation technique on hospitalization rates for septic events related to dialysis access. <i>Hemodialysis International</i> , 2010, 14, 451-463.	0.9	61
182	Coagulase-negative staphylococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 936 cases. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3386-3392.	0.7	60
183	Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease. <i>Stroke</i> , 2021, 52, 1545-1556.	2.0	60
184	Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). <i>BMJ Open</i> , 2018, 8, e018794.	1.9	60
185	Evidence-based guide to slowing the progression of early renal insufficiency. <i>Internal Medicine Journal</i> , 2004, 34, 50-57.	0.8	59
186	Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. <i>Kidney International</i> , 2013, 83, 503-510.	5.2	59
187	HMG CoA reductase inhibitors (statins) for kidney transplant recipients. <i>The Cochrane Library</i> , 2015, 2015, CD005019.	2.8	58
188	Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. , 2004, , CD004679.		57
189	Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 881-889.	0.7	57
190	Association Between Duration of Delayed Graft Function, Acute Rejection, and Allograft Outcome After Deceased Donor Kidney Transplantation. <i>Transplantation</i> , 2019, 103, 412-419.	1.0	57
191	Higher rate and earlier peritonitis in Aboriginal patients compared to non-Aboriginal patients with end-stage renal failure maintained on peritoneal dialysis in Australia: Analysis of ANZDATA. <i>Nephrology</i> , 2005, 10, 192-197.	1.6	56
192	Remote indigenous peritoneal dialysis patients have higher risk of peritonitis, technique failure, all-cause and peritonitis-related mortality. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3366-3372.	0.7	56
193	Indoxyl sulphate and kidney disease: Causes, consequences and interventions. <i>Nephrology</i> , 2016, 21, 170-177.	1.6	56
194	Regional variation in the treatment and prevention of peritoneal dialysis-related infections in the Peritoneal Dialysis Outcomes and Practice Patterns Study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 2118-2126.	0.7	56
195	Recovery of gastrointestinal function after renal transplantation in a patient with sclerosing peritonitis secondary to continuous ambulatory peritoneal dialysis. <i>American Journal of Kidney Diseases</i> , 1995, 26, 658-661.	1.9	55
196	Dental Health and Mortality in People With End-Stage Kidney Disease Treated With Hemodialysis: A Multinational Cohort Study. <i>American Journal of Kidney Diseases</i> , 2015, 66, 666-676.	1.9	55
197	ISPD Cardiovascular and Metabolic Guidelines in Adult Peritoneal Dialysis Patients Part II "Management of Various Cardiovascular Complications. <i>Peritoneal Dialysis International</i> , 2015, 35, 388-396.	2.3	55
198	Quantification of free mycophenolic acid and its glucuronide metabolite in human plasma by liquid-chromatography using mass spectrometric and ultraviolet absorbance detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 799, 157-163.	2.3	54

#	ARTICLE	IF	CITATIONS
199	Novel renoprotective actions of erythropoietin: New uses for an old hormone (Review Article). <i>Nephrology</i> , 2006, 11, 306-312.	1.6	54
200	A randomised controlled trial of Heparin versus Ethanol Lock Therapy for the prevention of Catheter Associated infection in Haemodialysis patients – the HEALTHY-CATH trial. <i>BMC Nephrology</i> , 2012, 13, 146.	1.8	54
201	HMG CoA reductase inhibitors (statins) for dialysis patients. <i>The Cochrane Library</i> , 2014, 2014, CD004289.	2.8	54
202	Center-Specific Factors Associated with Peritonitis Risk – A Multi-Center Registry Analysis. <i>Peritoneal Dialysis International</i> , 2016, 36, 509-518.	2.3	54
203	Phosphate binders in patients with chronic kidney disease. <i>Australian Prescriber</i> , 2017, 40, 9-14.	1.0	54
204	Does Uric Acid Have a Pathogenetic Role in Graft Dysfunction and Hypertension in Renal Transplant Recipients?. <i>Transplantation</i> , 2005, 80, 1565-1571.	1.0	53
205	Dietary protein restriction as a treatment for slowing chronic kidney disease progression: The case against (Review Article). <i>Nephrology</i> , 2006, 11, 58-62.	1.6	53
206	Treatment Options for Sexual Dysfunction in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 985-995.	4.5	53
207	The roles of IGF-I and IGFBP-3 in the regulation of proximal tubule, and renal cell carcinoma cell proliferation. <i>Kidney International</i> , 2004, 65, 1272-1279.	5.2	52
208	Plant community composition, not diversity, regulates soil respiration in grasslands. <i>Biology Letters</i> , 2008, 4, 345-348.	2.3	52
209	Streptococcal peritonitis in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 287 cases. <i>BMC Nephrology</i> , 2009, 10, 19.	1.8	52
210	Prevalence and patterns of cognitive impairment in adult hemodialysis patients: the COGNITIVE-HD study. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1197-1206.	0.7	52
211	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2653-2666.	6.1	52
212	Human renal fibroblasts modulate proximal tubule cell growth and transport via the IGF-I axis. <i>Kidney International</i> , 1997, 52, 1486-1496.	5.2	51
213	The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2016, 68, 554-563.	1.9	51
214	Quality of life of children and adolescents with chronic kidney disease: a cross-sectional study. <i>Archives of Disease in Childhood</i> , 2019, 104, 134-140.	1.9	51
215	Alkyldimethylaminoethyl ester iodides for improved analysis of fatty acids by electrospray ionization tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2000, 14, 2019-2024.	1.5	50
216	An Incident Cohort Study Comparing Survival on Home Hemodialysis and Peritoneal Dialysis (Australia) <i>Tj ETQq0 0 0 rgBT /Overlock 10</i> <i>Nephrology: CJASN</i> , 2015, 10, 1397-1407.	4.5	50

#	ARTICLE	IF	CITATIONS
217	Standardized Outcomes in Nephrologyâ€™Peritoneal Dialysis (SONG-PD): Study Protocol for Establishing a Core Outcome Set in PD. <i>Peritoneal Dialysis International</i> , 2017, 37, 639-647.	2.3	50
218	Correlates of subclinical left ventricular dysfunction in ESRD. <i>American Journal of Kidney Diseases</i> , 2003, 41, 1016-1025.	1.9	49
219	Pyrrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3377-3388.	0.7	49
220	The beliefs and expectations of patients and caregivers about home haemodialysis: an interview study. <i>BMJ Open</i> , 2013, 3, e002148.	1.9	49
221	The Association between Peritoneal Dialysis Modality and Peritonitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1091-1097.	4.5	49
222	How Safe Are Common Analgesics for the Treatment of Acute Pain for Children? A Systematic Review. <i>Pain Research and Management</i> , 2016, 2016, 1-15.	1.8	49
223	Length of time on peritoneal dialysis and encapsulating peritoneal sclerosis: position paper for ISPD. <i>Peritoneal Dialysis International</i> , 2009, 29, 595-600.	2.3	49
224	Severe Toxicity Associated with a Markedly Elevated Mycophenolic Acid Free Fraction in a Renal Transplant Recipient. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 453-455.	2.0	48
225	Should an Oral Glucose Tolerance Test Be Performed Routinely in All Renal Transplant Recipients?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 100-108.	4.5	48
226	Daily Variation in Death in Patients Treated by Long-term Dialysis: Comparison of In-Center Hemodialysis to Peritoneal and Home Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2013, 61, 96-103.	1.9	48
227	Clioma Surgical Aspirate: A Viable Source of Tumor Tissue for Experimental Research. <i>Cancers</i> , 2013, 5, 357-371.	3.7	48
228	A flow injection electrospray ionization tandem mass spectrometric method for the simultaneous measurement of trimethylamine and trimethylamine oxide in urine. <i>Journal of Mass Spectrometry</i> , 2008, 43, 495-499.	1.6	46
229	<i>Corynebacterium peritonitis</i> in Australian peritoneal dialysis patients: predictors, treatment and outcomes in 82 cases. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3834-3839.	0.7	46
230	Challenges of conducting a trial of uric-acid-lowering therapy in CKD. <i>Nature Reviews Nephrology</i> , 2011, 7, 295-300.	9.6	46
231	Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients. <i>BMC Nephrology</i> , 2014, 15, 8.	1.8	46
232	The role of the gastrointestinal tract and microbiota on uremic toxins and chronic kidney disease development. <i>Clinical and Experimental Nephrology</i> , 2017, 21, 7-15.	1.6	46
233	Biocompatible dialysis fluids for peritoneal dialysis. <i>The Cochrane Library</i> , 2018, 2018, CD007554.	2.8	46
234	Meaning of empowerment in peritoneal dialysis: focus groups with patients and caregivers. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1949-1958.	0.7	46



#	ARTICLE	IF	CITATIONS
235	Dosing of Gentamicin in Patients With End-Stage Renal Disease Receiving Hemodialysis. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1259-1267.	2.0	45
236	Effect of Early Initiation of Dialysis on Cardiac Structure and Function: Results From the Echo Substudy of the IDEAL Trial. <i>American Journal of Kidney Diseases</i> , 2013, 61, 262-270.	1.9	45
237	The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled. <i>Seminars in Dialysis</i> , 2018, 31, 244-257.	1.3	45
238	Oxidative Stress and Cell Senescence Combine to Cause Maximal Renal Tubular Epithelial Cell Dysfunction and Loss in an in vitro Model of Kidney Disease. <i>Nephron Experimental Nephrology</i> , 2013, 122, 123-130.	2.2	45
239	Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. <i>Heart</i> , 2006, 92, 1402-1408.	2.9	44
240	Prevalence and correlates of erectile dysfunction in men on chronic haemodialysis: a multinational cross-sectional study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2479-2488.	0.7	44
241	NR1I2 Polymorphisms Are Related to Tacrolimus Dose-Adjusted Exposure and BK Viremia in Adult Kidney Transplantation. <i>Transplantation</i> , 2012, 94, 1025-1032.	1.0	44
242	Arbuscular mycorrhizal fungi reduce the differences in competitiveness between dominant and subordinate plant species. <i>Mycorrhiza</i> , 2013, 23, 267-277.	2.8	44
243	A randomized trial of sodium-restriction on kidney function, fluid volume and adipokines in CKD patients. <i>BMC Nephrology</i> , 2014, 15, 57.	1.8	44
244	The Kidney-Gut Axis: Implications for Nutrition Care. , 2015, 25, 399-403.		44
245	Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. <i>Kidney International</i> , 2016, 89, 1337-1345.	5.2	44
246	Evaluation of limited sampling methods for estimation of tacrolimus exposure in adult kidney transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2011, 71, 207-223.	2.4	43
247	The Outcomes of Patients with ESRD and ANCA-Associated Vasculitis in Australia and New Zealand. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 773-780.	4.5	43
248	Oxidative stress-induced alterations in PPAR- $\beta$ and associated mitochondrial destabilization contribute to kidney cell apoptosis. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 307, F814-F822.	2.7	43
249	Survival after Kidney Transplantation during Childhood and Adolescence. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 392-400.	4.5	43
250	Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials. <i>American Journal of Kidney Diseases</i> , 2004, 44, 591-603.	1.9	43
251	Do aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?. <i>BMC Nephrology</i> , 2011, 12, 20.	1.8	42
252	Changes in serum prolactin, sex hormones and thyroid function with alternate nightly nocturnal home haemodialysis. <i>Nephrology</i> , 2012, 17, 42-47.	1.6	42



#	ARTICLE	IF	CITATIONS
253	Unconventional Human T Cells Accumulate at the Site of Infection in Response to Microbial Ligands and Induce Local Tissue Remodeling. <i>Journal of Immunology</i> , 2016, 197, 2195-2207.	0.8	42
254	Dimethylaminoethyl esters for trace, rapid analysis of fatty acids by electrospray tandem mass spectrometry. , 1999, 13, 2388-2393.		41
255	Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 776-783.	0.7	41
256	Treatment for peritoneal dialysis-associated peritonitis. , 2008, , CD005284.		41
257	Obesity and hypertension have differing oxidant handling molecular pathways in age-related chronic kidney disease. <i>Mechanisms of Ageing and Development</i> , 2009, 130, 129-138.	4.6	41
258	Consumer involvement in topic and outcome selection in the development of clinical practice guidelines. <i>Health Expectations</i> , 2012, 15, 410-423.	2.6	41
259	SYNbiotics Easing Renal failure by improving Gut microbiology (SYNERGY): a protocol of placebo-controlled randomised cross-over trial. <i>BMC Nephrology</i> , 2014, 15, 106.	1.8	41
260	Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. <i>The Cochrane Library</i> , 2017, 2017, CD004679.	2.8	41
261	Global overview of health systems oversight and financing for kidney care. <i>Kidney International Supplements</i> , 2018, 8, 41-51.	14.2	41
262	Vascular Access Outcomes Reported in Maintenance Hemodialysis Trials: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2018, 71, 382-391.	1.9	41
263	The effect of oral iron administration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. <i>Transplantation</i> , 2004, 77, 206-209.	1.0	40
264	Perioperative Point-of-Care Ultrasonography. <i>Anesthesiology</i> , 2011, 115, 460-462.	2.5	40
265	PAR2-induced inflammatory responses in human kidney tubular epithelial cells. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, F737-F750.	2.7	40
266	End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2277-2286.	0.7	40
267	Focus on peritoneal dialysis training: working to decrease peritonitis rates. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, gfu403.	0.7	40
268	Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The <i>bal</i> ANZ Trial. <i>Peritoneal Dialysis International</i> , 2017, 37, 283-289.	2.3	40
269	Antimicrobial agents to prevent peritonitis in peritoneal dialysis: A systematic review of randomized controlled trials. <i>American Journal of Kidney Diseases</i> , 2004, 44, 591-603.	1.9	40
270	Free Fatty Acids Are Associated with Obesity, Insulin Resistance, and Atherosclerosis in Renal Transplant Recipients. <i>Transplantation</i> , 2005, 80, 937-944.	1.0	39

#	ARTICLE	IF	CITATIONS
271	Quality of life and alternate nightly nocturnal home hemodialysis. <i>Hemodialysis International</i> , 2010, 14, 29-38.	0.9	39
272	Erythropoietin protects against apoptosis and increases expression of non-neuronal cell markers in the hypoxia-injured developing brain. <i>Journal of Pathology</i> , 2011, 224, 101-109.	4.5	39
273	Anti-oxidant pathways are stimulated by mesenchymal stromal cells in renal repair after ischemic injury. <i>Cytotherapy</i> , 2012, 14, 162-172.	0.7	39
274	Feasibility and construct validity of a frailty index for patients with chronic kidney disease. <i>Australasian Journal on Ageing</i> , 2015, 34, E9-12.	0.9	39
275	Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2018, 72, 62-74.	1.9	39
276	Dietary Potassium Intake and All-Cause Mortality in Adults Treated with Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1851-1861.	4.5	39
277	Frequency and severity of acute rejection in live- versus cadaveric-donor renal transplants. <i>Transplantation</i> , 2003, 76, 1452-1457.	1.0	38
278	Catheter type, placement and insertion techniques for preventing peritonitis in peritoneal dialysis patients. <i>The Cochrane Library</i> , 2004, , CD004680.	2.8	38
279	Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells. <i>Kidney International</i> , 2005, 67, 1315-1329.	5.2	38
280	A modified Girard derivatizing reagent for universal profiling and trace analysis of aldehydes and ketones by electrospray ionization tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 2926-2932.	1.5	38
281	Isolation, propagation and characterization of primary tubule cell culture from human kidney (Methods in Renal Research). <i>Nephrology</i> , 2007, 12, 155-159.	1.6	38
282	Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 381-387.	0.7	38
283	Functional significance of erythropoietin in renal cell carcinoma. <i>BMC Cancer</i> , 2013, 13, 14.	2.6	38
284	A Trial Evaluating Mid Cut-Off Value Membrane Clearance of Albumin and Light Chains in Hemodialysis Patients: A Safety Device Study. <i>Blood Purification</i> , 2020, 49, 468-478.	1.8	38
285	Elevated white cell count at commencement of peritoneal dialysis predicts overall and cardiac mortality. <i>Kidney International</i> , 2005, 67, 738-743.	5.2	37
286	Treatment of Peritoneal Dialysis-Associated Peritonitis: A Systematic Review of Randomized Controlled Trials. <i>American Journal of Kidney Diseases</i> , 2007, 50, 967-988.	1.9	37
287	An <i>in vitro</i> investigation of herbs traditionally used for kidney and urinary system disorders: Potential therapeutic and toxic effects. <i>Nephrology</i> , 2009, 14, 70-79.	1.6	37
288	End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 455-461.	0.7	37

#	ARTICLE	IF	CITATIONS
289	The Association between Body Mass Index and Mortality in Incident Dialysis Patients. <i>PLoS ONE</i> , 2014, 9, e114897.	2.5	37
290	Paediatric pain management practice and policies across Alberta emergency departments. <i>Paediatrics and Child Health</i> , 2014, 19, 190-194.	0.6	37
291	Treatment for peritoneal dialysis-associated peritonitis. <i>The Cochrane Library</i> , 2014, , CD005284.	2.8	37
292	Prevention of peritoneal dialysis-related infections. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1461-1472.	0.7	37
293	Global Kidney Health Atlas (GKHA): design and methods. <i>Kidney International Supplements</i> , 2017, 7, 145-153.	14.2	37
294	The effect of rank, lithotype and roughness on contact angle measurements in coal cleats. <i>International Journal of Coal Geology</i> , 2017, 179, 302-315.	5.0	37
295	Recommendations for the use of icodextrin in peritoneal dialysis patients. Review Article. <i>Nephrology</i> , 2003, 8, 1-7.	1.6	36
296	A Comparison of Peritoneal Equilibration Tests Performed 1 and 4 Weeks after PD Commencement. <i>Peritoneal Dialysis International</i> , 2004, 24, 460-465.	2.3	36
297	Use of serum creatinine concentration to assess level of kidney function. <i>Nephrology</i> , 2005, 10, S133-76.	1.6	36
298	Cutaneous manifestations of cytomegalovirus disease in renal transplant recipients: a case series. <i>Transplant Infectious Disease</i> , 2008, 10, 209-213.	1.7	36
299	The $\beta$ -Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 902-911.	1.9	36
300	Capturing and monitoring global differences in untreated and treated end-stage kidney disease, kidney replacement therapy modality, and outcomes. <i>Kidney International Supplements</i> , 2020, 10, e3-e9.	14.2	36
301	Mineral metabolism, bone histomorphometry and vascular calcification in alternate night nocturnal haemodialysis. <i>Nephrology</i> , 2007, 12, 224-233.	1.6	35
302	Peritoneal Small Solute Clearance is Nonlinearly Related to Patient Survival in the Australian and New Zealand Peritoneal Dialysis Patient Populations. <i>Peritoneal Dialysis International</i> , 2009, 29, 637-646.	2.3	35
303	Evaluation of Dietetic Advice for Modification of Cardiovascular Disease Risk Factors in Renal Transplant Recipients. , 2011, 21, 462-471.		35
304	Free amino acid quantification by LC-MS/MS using derivatization generated isotope-labelled standards. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 1345-1352.	2.3	35
305	Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week. <i>Transplant International</i> , 2012, 25, 1182-1193.	1.6	35
306	Increased progression to kidney fibrosis after erythropoietin is used as a treatment for acute kidney injury. <i>American Journal of Physiology - Renal Physiology</i> , 2014, 306, F681-F692.	2.7	35

#	ARTICLE	IF	CITATIONS
307	Chinese herbal medicine for diabetic kidney disease: a systematic review and meta-analysis of randomised placebo-controlled trials. <i>BMJ Open</i> , 2019, 9, e025653.	1.9	35
308	Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2020, 76, 321-330.	1.9	35
309	The Role of DEXA Bone Densitometry in Evaluating Renal Osteodystrophy in Continuous Ambulatory Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 1996, 16, 34-40.	2.3	34
310	Quantification of Glutamine in Dried Blood Spots and Plasma by Tandem Mass Spectrometry for the Biochemical Diagnosis and Monitoring of Ornithine Transcarbamylase Deficiency. <i>Clinical Chemistry</i> , 2003, 49, 681-684.	3.2	34
311	Ketosteroid profiling using Girard T derivatives and electrospray ionization tandem mass spectrometry: direct plasma analysis of androstenedione, 17-hydroxyprogesterone and cortisol. <i>Rapid Communications in Mass Spectrometry</i> , 2005, 19, 193-200.	1.5	34
312	Potential physiological and pathophysiological roles for protease-activated receptor-2 in the kidney (Review Article). <i>Nephrology</i> , 2007, 12, 36-43.	1.6	34
313	Isolation and Primary Culture of Human Proximal Tubule Cells. <i>Methods in Molecular Biology</i> , 2009, 466, 19-24.	0.9	34
314	Clinical Causes of Inflammation in Peritoneal Dialysis Patients. <i>International Journal of Nephrology</i> , 2014, 2014, 1-9.	1.3	34
315	Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1940-1947.	0.7	34
316	Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1425-1436.	0.7	34
317	Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients?. <i>Transplantation</i> , 2002, 73, 1158-1163.	1.0	33
318	Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. <i>Pathology</i> , 2002, 34, 263-266.	0.6	33
319	Medicinal herbal extracts - renal friend or foe? Part two: Herbal extracts with potential renal benefits. <i>Nephrology</i> , 2004, 9, 400-405.	1.6	33
320	<i>Dioscorea villosa</i> (wild yam) induces chronic kidney injury via pro-fibrotic pathways. <i>Food and Chemical Toxicology</i> , 2008, 46, 3122-3131.	3.6	33
321	End-stage kidney disease due to scleroderma—outcomes in 127 consecutive ANZDATA registry cases. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3165-3171.	0.7	33
322	A Randomized Controlled Trial of Intravenous or Oral Iron for Posttransplant Anemia in Kidney Transplantation. <i>Transplantation</i> , 2012, 93, 822-826.	1.0	33
323	Low GDP Solution and Glucose-Sparing Strategies for Peritoneal Dialysis. <i>Seminars in Nephrology</i> , 2017, 37, 30-42.	1.6	33
324	The Association of Mediterranean and DASH Diets with Mortality in Adults on Hemodialysis: The DIET-HD Multinational Cohort Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1741-1751.	6.1	33

#	ARTICLE	IF	CITATIONS
325	Physical activity and exercise in peritoneal dialysis: International Society for Peritoneal Dialysis and the Global Renal Exercise Network practice recommendations. <i>Peritoneal Dialysis International</i> , 2022, 42, 8-24.	2.3	33
326	A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1879-1884.	0.7	32
327	In vivo and in vitro models demonstrate a role for caveolin-1 in the pathogenesis of ischaemic acute renal failure. <i>Journal of Pathology</i> , 2003, 200, 396-405.	4.5	32
328	Therapeutic Monitoring of Mycophenolate in Transplantation: Is It Justified?. <i>Current Drug Metabolism</i> , 2009, 10, 179-187.	1.2	32
329	Effect of Timing of Dialysis Commencement on Clinical Outcomes of Patients with Planned Initiation of Peritoneal Dialysis in the Ideal Trial. <i>Peritoneal Dialysis International</i> , 2012, 32, 595-604.	2.3	32
330	Association between causes of peritoneal dialysis technique failure and all-cause mortality. <i>Scientific Reports</i> , 2018, 8, 3980.	3.3	32
331	Measurement of plasma pristanic, phytanic and very long chain fatty acids by liquid chromatography-electrospray tandem mass spectrometry for the diagnosis of peroxisomal disorders. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 798, 159-162.	2.3	31
332	A single-centre experience of post-renal transplant lymphoproliferative disorder. <i>Transplant International</i> , 2003, 16, 529-536.	1.6	31
333	Cardiorespiratory Fitness Is Related to Physical Inactivity, Metabolic Risk Factors, and Atherosclerotic Burden in Glucose-Intolerant Renal Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 1275-1283.	4.5	31
334	Erythropoietin administration protects against functional impairment and cell death after ischaemic renal injury in pigs. <i>BJU International</i> , 2007, 99, 162-165.	2.5	31
335	Recovery of renal function in end-stage renal failure—comparison between peritoneal dialysis and haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2825-2831.	0.7	31
336	Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2028-2036.	0.7	31
337	Impact of Estimated GFR Reporting on Late Referral Rates and Practice Patterns for End-Stage Kidney Disease Patients: A Multilevel Logistic Regression Analysis Using the Australia and New Zealand Dialysis and Transplant Registry (ANZDATA). <i>American Journal of Kidney Diseases</i> , 2014, 64, 359-366.	1.9	31
338	Dietary Patterns and Clinical Outcomes in Chronic Kidney Disease: The CKD.QLD Nutrition Study. , 2017, 27, 175-182.		31
339	Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure. <i>Nephrology</i> , 2005, 10, 33-36.	1.6	30
340	A Randomized Controlled Trial of Fludrocortisone for the Treatment of Hyperkalemia in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2006, 47, 809-814.	1.9	30
341	Outcomes of transplants from patients with small renal tumours, live unrelated donors and dialysis wait-listed patients. <i>Transplant International</i> , 2010, 23, 476-483.	1.6	30
342	Prevention, detection and management of early chronic kidney disease: A systematic review of clinical practice guidelines. <i>Nephrology</i> , 2013, 18, 592-604.	1.6	30

#	ARTICLE	IF	CITATIONS
343	Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1845-1855.	4.5	30
344	The Long-Term Impact of Renin-Angiotensin System (RAS) Inhibition on Cardiorenal Outcomes (LIRICO): A Randomized, Controlled Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2890-2899.	6.1	30
345	Variation in Peritoneal Dialysis-Related Peritonitis Outcomes in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS). <i>American Journal of Kidney Diseases</i> , 2022, 79, 45-55.e1.	1.9	30
346	The relationship of a clonal outbreak of <i>Enterococcus faecium</i> vanA to methicillin-resistant <i>Staphylococcus aureus</i> incidence in an Australian hospital. <i>Journal of Hospital Infection</i> , 2001, 48, 43-54.	2.9	29
347	Prevention of Progression of Kidney Disease. <i>Nephrology</i> , 2006, 11, S2-S197.	1.6	29
348	Predictors of Renal Recovery in Australian and New Zealand end-Stage Renal Failure Patients Treated with Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2007, 27, 184-191.	2.3	29
349	Estimated donor glomerular filtration rate is the most important donor characteristic predicting graft function in recipients of kidneys from live donors. <i>Transplant International</i> , 2007, 20, 64-72.	1.6	29
350	A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. <i>British Journal of Haematology</i> , 2008, 141, 904-907.	2.5	29
351	Recent Clinical Trials of Pharmacologic Cardiovascular Interventions in Patients with Chronic Kidney Disease. <i>Reviews on Recent Clinical Trials</i> , 2008, 3, 79-88.	0.8	29
352	Depression and sexual dysfunction in chronic kidney disease: a narrative review of the evidence in areas of significant unmet need. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3420-3428.	0.7	29
353	Evidence for Steroidogenic Potential in Human Prostate Cell Lines and Tissues. <i>American Journal of Pathology</i> , 2012, 181, 1078-1087.	3.8	29
354	N-Terminal Pro-B-Type Natriuretic Peptide Variability in Stable Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 620-629.	4.5	29
355	A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial. <i>American Journal of Kidney Diseases</i> , 2015, 65, 49-57.	1.9	29
356	Peritoneal dialysis practice in Australia and New Zealand: A call to sustain the action. <i>Nephrology</i> , 2016, 21, 535-546.	1.6	29
357	Infection-Related Mortality in Recipients of a Kidney Transplant in Australia and New Zealand. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1484-1492.	4.5	29
358	Feasibility and acceptability of telehealth coaching to promote healthy eating in chronic kidney disease: a mixed-methods process evaluation. <i>BMJ Open</i> , 2019, 9, e024551.	1.9	29
359	Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis-International Results from PDOPPS. <i>Kidney International Reports</i> , 2021, 6, 313-324.	0.8	29
360	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Western Europe. <i>Kidney International Supplements</i> , 2021, 11, e106-e118.	14.2	29



#	ARTICLE	IF	CITATIONS
361	The Initiating Dialysis Early and Late (IDEAL) study: study rationale and design. <i>Peritoneal Dialysis International</i> , 2004, 24, 176-81.	2.3	29
362	Fibrogenic Effects of Cyclosporin A on the Tubulointerstitium: Role of Cytokines and Growth Factors. <i>Nephron Experimental Nephrology</i> , 1999, 7, 470-478.	2.2	28
363	Continuous Quality Improvement Initiatives to Sustainably Reduce Peritoneal Dialysis-Related Infections in Australia and New Zealand. <i>Peritoneal Dialysis International</i> , 2016, 36, 472-477.	2.3	28
364	A Coaching Program to Improve Dietary Intake of Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 330-340.	4.5	28
365	Analysis of amino acids as formamidene butyl esters by electrospray ionization tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2001, 15, 2198-2205.	1.5	27
366	A cluster randomized controlled trial comparing three methods of disseminating practice guidelines for children with croup [ISRCTN73394937]. <i>Implementation Science</i> , 2006, 1, 10.	6.9	27
367	Transport characteristics of human proximal tubule cells in primary culture. <i>Nephrology</i> , 1997, 3, 183-194.	1.6	27
368	The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study. <i>BMC Nephrology</i> , 2012, 13, 41.	1.8	27
369	Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015, 53, 715-22.	2.3	27
370	Microbiota and the nitrogen cycle: Implications in the development and progression of CVD and CKD. <i>Nitric Oxide - Biology and Chemistry</i> , 2016, 57, 64-70.	2.7	27
371	Health data linkage research in Australia remains challenging. <i>Internal Medicine Journal</i> , 2019, 49, 539-544.	0.8	27
372	Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. <i>Cancer Biology and Therapy</i> , 2007, 6, 1944-1950.	3.4	26
373	HMG CoA reductase inhibitors (statins) for kidney transplant recipients. , 2009, , CD005019.		26
374	Exploring Differences in the Clinical Management of Pediatric Mental Health in the Emergency Department. <i>Pediatric Emergency Care</i> , 2011, 27, 275-283.	0.9	26
375	Association of Biocompatible Peritoneal Dialysis Solutions with Peritonitis Risk, Treatment, and Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1556-1563.	4.5	26
376	End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases. <i>American Journal of Nephrology</i> , 2015, 42, 177-184.	3.1	26
377	Vitamin D status and mortality risk among patients on dialysis: a systematic review and meta-analysis of observational studies. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1742-1751.	0.7	26
378	Patient survival on haemodiafiltration and haemodialysis: a cohort study using the Australia and New Zealand Dialysis and Transplant Registry. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 326-338.	0.7	26



#	ARTICLE	IF	CITATIONS
379	Peritoneal dialysis-associated peritonitis outcomes reported in trials and observational studies: A systematic review. <i>Peritoneal Dialysis International</i> , 2020, 40, 132-140.	2.3	26
380	Global Estimates of Capacity for Kidney Transplantation in World Countries and Regions. <i>Transplantation</i> , 2022, 106, 1113-1122.	1.0	26
381	Sustaining ecosystem services in ancient limestone grassland: importance of major component plants and community composition. <i>Journal of Ecology</i> , 2008, 96, 894-902.	4.0	25
382	The HoneyPot Study Protocol: A Randomized Controlled Trial of Exit-Site Application of Medihoney Antibacterial Wound Gel for the Prevention of Catheter-Associated Infections in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2009, 29, 303-309.	2.3	25
383	The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with Chronic Kidney Disease: a randomised controlled trial. <i>BMC Nephrology</i> , 2009, 10, 41.	1.8	25
384	Higher Levels of Physical Activity Are Associated With a Lower Risk of Abnormal Glucose Tolerance in Renal Transplant Recipients. , 2009, 19, 304-313.		25
385	Epidemiology and outcomes of peritonitis in children on peritoneal dialysis in Australasia. <i>Pediatric Nephrology</i> , 2010, 25, 1739-1745.	1.7	25
386	Vitamin D does not improve the metabolic health of patients with chronic kidney disease stage 3-4: A randomized controlled trial. <i>Nephrology</i> , 2013, 18, 26-35.	1.6	25
387	Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD. <i>BMC Nephrology</i> , 2017, 18, 281.	1.8	25
388	Patient-reported advantages and disadvantages of peritoneal dialysis: results from the PDOPPS. <i>BMC Nephrology</i> , 2019, 20, 116.	1.8	25
389	Current status of health systems financing and oversight for end-stage kidney disease care: a cross-sectional global survey. <i>BMJ Open</i> , 2021, 11, e047245.	1.9	25
390	Kidney care in low- and middle-income countries. <i>Clinical Nephrology</i> , 2020, 93, 21-30.	0.7	25
391	Synbiotics Easing Renal Failure by Improving Gut Microbiology II (SYNERGY II): A Feasibility Randomized Controlled Trial. <i>Nutrients</i> , 2021, 13, 4481.	4.1	25
392	Analysis of alcohols, as dimethylglycine esters, by electrospray ionization tandem mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2001, 36, 277-283.	1.6	24
393	Therapeutic value of orally administered silibinin in renal cell carcinoma: manipulation of insulin-like growth factor binding protein-3 levels. <i>BJU International</i> , 2007, 100, 438-444.	2.5	24
394	Prevention of access-related infection in dialysis. <i>Expert Review of Anti-Infective Therapy</i> , 2009, 7, 1185-1200.	4.4	24
395	Rationale and design of the balANZ trial: A randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function. <i>BMC Nephrology</i> , 2010, 11, 25.	1.8	24
396	A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4146-4153.	0.7	24

#	ARTICLE	IF	CITATIONS
397	Renal services disaster planning: Lessons learnt from the 2011 Queensland floods and North Queensland cyclone experiences. <i>Nephrology</i> , 2013, 18, 41-46.	1.6	24
398	Partitioning of soil phosphorus regulates competition between <i>Vaccinium vitis-idaea</i> and <i>Deschampsia cespitosa</i> . <i>Ecology and Evolution</i> , 2013, 3, 4243-4252.	1.9	24
399	Nutrition and dietary intake and their association with mortality and hospitalisation in adults with chronic kidney disease treated with haemodialysis: protocol for DIET-HD, a prospective multinational cohort study. <i>BMJ Open</i> , 2015, 5, e006897-e006897.	1.9	24
400	Global coverage of health information systems for kidney disease: availability, challenges, and opportunities for development. <i>Kidney International Supplements</i> , 2018, 8, 74-81.	14.2	24
401	Clinical Studies of Interventions to Mitigate Cardiovascular Risk in Peritoneal Dialysis Patients. <i>Seminars in Nephrology</i> , 2018, 38, 277-290.	1.6	24
402	International Anemia Prevalence and Management in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2019, 39, 539-546.	2.3	24
403	Chronic exposure to cadmium is associated with a marked reduction in glomerular filtration rate. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 468-475.	2.9	24
404	Transition between Different Renal Replacement Modalities: Gaps in Knowledge and Care—the Integrated Research Initiative. <i>Peritoneal Dialysis International</i> , 2019, 39, 4-12.	2.3	24
405	Associations of Cognitive Function and Education Level With All-Cause Mortality in Adults on Hemodialysis: Findings From the COGNITIVE-HD Study. <i>American Journal of Kidney Diseases</i> , 2019, 74, 452-462.	1.9	24
406	Multicentre registry data analysis comparing outcomes of culture-negative peritonitis and different subtypes of culture-positive peritonitis in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2020, 40, 47-56.	2.3	24
407	Development of a framework for minimum and optimal safety and quality standards for hemodialysis and peritoneal dialysis. <i>Kidney International Supplements</i> , 2020, 10, e55-e62.	14.2	24
408	Hemodialysis Use and Practice Patterns: An International Survey Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 326-335.e1.	1.9	24
409	A randomized trial comparing 1.25 mmol/l calcium dialysate to 1.75 mmol/l calcium dialysate in CAPD patients. <i>Nephrology Dialysis Transplantation</i> , 1996, 11, 88-93.	0.7	23
410	Plant genotypic diversity does not beget root-fungal species diversity. <i>Plant and Soil</i> , 2010, 336, 107-111.	3.7	23
411	Interventions for treating sexual dysfunction in patients with chronic kidney disease. <i>The Cochrane Library</i> , 2010, , CD007747.	2.8	23
412	Clinician beliefs and attitudes about home haemodialysis: a multinational interview study. <i>BMJ Open</i> , 2012, 2, e002146.	1.9	23
413	Role of Nutrition Impact Symptoms in Predicting Nutritional Status and Clinical Outcome in Hemodialysis Patients: A Potential Screening Tool. , 2013, 23, 302-307.		23
414	Baseline Serum Interleukin-6 Predicts Cardiovascular Events in Incident Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2015, 35, 35-42.	2.3	23

#	ARTICLE	IF	CITATIONS
415	The role of cGMP and its signaling pathways in kidney disease. American Journal of Physiology - Renal Physiology, 2016, 311, F671-F681.	2.7	23
416	Core Outcome Domains for Trials in Autosomal Dominant Polycystic Kidney Disease: An International Delphi Survey. American Journal of Kidney Diseases, 2020, 76, 361-373.	1.9	23
417	Postoperative mortality in patients on chronic dialysis following elective surgery: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0234402.	2.5	23
418	Assessing Global Kidney Nutrition Care. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 38-52.	4.5	23
419	Disseminated Pyogenic Mycoplasma pneumoniae Infection in a Renal Transplant Recipient, Detected by Broad-Range Polymerase Chain Reaction. Clinical Infectious Diseases, 2004, 39, e98-e99.	5.8	22
420	Small solute clearance targets in peritoneal dialysis. Nephrology, 2005, 10, S81-S85.	1.6	22
421	The influence of obesity on the development and survival outcomes of chronic kidney disease. Advances in Chronic Kidney Disease, 2005, 12, 49-55.	1.4	22
422	Analysis of succinylacetone, as a Girard T derivative, in urine and dried bloodspots by flow injection electrospray ionization tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2007, 21, 59-63.	1.5	22
423	Editorial: Aminoglycosides in Hemodialysis Patients: Is the Current Practice of Post Dialysis Dosing Appropriate?. Seminars in Dialysis, 2009, 22, 225-230.	1.3	22
424	Patient samples of renal cell carcinoma show reduced expression of TRAF1 compared with normal kidney and functional studies in vitro indicate TRAF1 promotes apoptosis: potential for targeted therapy. Pathology, 2012, 44, 453-459.	0.6	22
425	Con: Buttonhole cannulation of arteriovenous fistulae. Nephrology Dialysis Transplantation, 2016, 31, 525-528.	0.7	22
426	Type 2 diabetes in patients with end-stage kidney disease: influence on cardiovascular disease-related mortality risk. Medical Journal of Australia, 2018, 209, 440-446.	1.7	22
427	Identifying critically important vascular access outcomes for trials in haemodialysis: an international survey with patients, caregivers and health professionals. Nephrology Dialysis Transplantation, 2020, 35, 657-668.	0.7	22
428	Workforce capacity for the care of patients with kidney failure across world countries and regions. BMJ Global Health, 2021, 6, e004014.	4.7	22
429	Hemodialysis versus continuous veno-venous hemodiafiltration in the management of severe valproate overdose. Clinical Nephrology, 2003, 59, 56-58.	0.7	22
430	Fibrogenic stresses activate different mitogen-activated protein kinase pathways in renal epithelial, endothelial or fibroblast cell populations. Nephrology, 2003, 8, 196-204.	1.6	21
431	Apoptosis of tubulointerstitial chronic inflammatory cells in progressive renal fibrosis after cancer therapies. Translational Research, 2007, 150, 40-50.	5.0	21
432	What is the Optimal Fat Mass in Peritoneal Dialysis Patients?. Peritoneal Dialysis International, 2007, 27, 250-254.	2.3	21

#	ARTICLE	IF	CITATIONS
433	Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor. <i>Angiogenesis</i> , 2009, 12, 365-379.	7.2	21
434	BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression. <i>Journal of Transplantation</i> , 2011, 2011, 1-9.	0.5	21
435	Guidelines, policies, and barriers to kidney care: findings from a global survey. <i>Kidney International Supplements</i> , 2018, 8, 30-40.	14.2	21
436	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrologyâ€”Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2021, 77, 255-263.	1.9	21
437	A Systematic Review and Meta-Analysis on Effects of Bicarbonate Therapy on Kidney Outcomes. <i>Kidney International Reports</i> , 2021, 6, 695-705.	0.8	21
438	Isolated tuberculous pyomyositis in a renal transplant patient. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 743-743.	0.7	20
439	Interacting Roles of Myofibroblasts, Apoptosis and Fibrogenic Growth Factors in the Pathogenesis of Renal Tubulo-interstitial Fibrosis. <i>Growth Factors</i> , 2002, 20, 109-119.	1.7	20
440	Inhibition of nuclear factor kappa B transcription activity drives a synergistic effect of pyrrolidine dithiocarbamate and cisplatin for treatment of renal cell carcinoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2010, 15, 412-425.	4.9	20
441	Outcomes of Patients with Planned Initiation of Hemodialysis in the IDEAL Trial. <i>Contributions To Nephrology</i> , 2011, 171, 1-9.	1.1	20
442	Uremic Toxin Development in Living Kidney Donors. <i>Transplantation</i> , 2014, 97, 548-554.	1.0	20
443	Outcomes of integrated home dialysis care: a multi-centre, multi-national registry study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1897-1904.	0.7	20
444	Beyond Sodium, Phosphate and Potassium: Potential Dietary Interventions in Kidney Disease. <i>Seminars in Dialysis</i> , 2017, 30, 197-202.	1.3	20
445	Early Peritoneal Dialysis Technique Failure: Review. <i>Peritoneal Dialysis International</i> , 2018, 38, 319-327.	2.3	20
446	Identifying patientâ€™important outcomes in polycystic kidney disease: An international nominal group technique study. <i>Nephrology</i> , 2019, 24, 1214-1224.	1.6	20
447	Standardized Outcomes in Nephrologyâ€”Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease. <i>Kidney International</i> , 2019, 95, 1280-1283.	5.2	20
448	Analysis of isomeric long-chain hydroxy fatty acids by tandem mass spectrometry: application to the diagnosis of long-chain 3-hydroxyacyl CoA dehydrogenase deficiency. <i>Rapid Communications in Mass Spectrometry</i> , 2003, 17, 171-175.	1.5	19
449	Coca-Cola and kangaroos. <i>Lancet, The</i> , 2004, 364, 1190.	13.7	19
450	Proinflammatory and proliferative responses of human proximal tubule cells to PAR-2 activation. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F1441-F1449.	2.7	19

#	ARTICLE	IF	CITATIONS
451	An acid hydrolysis method for quantification of plasma free and total carnitine by flow injection tandem mass spectrometry. <i>Clinical Biochemistry</i> , 2010, 43, 1362-1367.	1.9	19
452	Repeated Peritoneal Dialysis-associated Peritonitis: A Multicenter Registry Study. <i>American Journal of Kidney Diseases</i> , 2012, 59, 84-91.	1.9	19
453	Oral disease in adults treated with hemodialysis: prevalence, predictors, and association with mortality and adverse cardiovascular events: the rationale and design of the ORAL Diseases in hemodialysis (ORAL-D) study, a prospective, multinational, longitudinal, observational, cohort study. <i>BMC Nephrology</i> , 2013, 14, 90.	1.8	19
454	The Role of Monitoring Vancomycin Levels in Patients with Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2015, 35, 222-228.	2.3	19
455	Post-transplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients. <i>Kidney International</i> , 2018, 94, 809-817.	5.2	19
456	Urgent-start peritoneal dialysis. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 631-640.	2.0	19
457	Recruitment and retention in clinical trials in chronic kidney disease: report from national workshops with patients, caregivers and health professionals. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 755-764.	0.7	19
458	Peritoneal small solute clearance is nonlinearly related to patient survival in the Australian and New Zealand peritoneal dialysis patient populations. <i>Peritoneal Dialysis International</i> , 2009, 29, 637-46.	2.3	19
459	Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders. <i>Nephrology</i> , 2004, 9, 406-413.	1.6	18
460	Synthesis of dicarboxylic acylcarnitines. <i>Chemistry and Physics of Lipids</i> , 2004, 129, 161-171.	3.2	18
461	Shining D' light on chronic kidney disease: Mechanisms that may underpin the cardiovascular benefit of vitamin D. <i>Nephrology</i> , 2011, 16, 351-367.	1.6	18
462	Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes. <i>International Journal of Nephrology</i> , 2012, 2012, 1-9.	1.3	18
463	Outcomes of <i>Corynebacterium</i> Peritonitis: A Multicenter Registry Analysis. <i>Peritoneal Dialysis International</i> , 2017, 37, 619-626.	2.3	18
464	Association of Kidney Function with Infections by Multidrug-Resistant Organisms: An Electronic Medical Record Analysis. <i>Scientific Reports</i> , 2018, 8, 13372.	3.3	18
465	An Intervention Design: Supporting Skills Development for Peritoneal Dialysis Trainers. <i>Peritoneal Dialysis International</i> , 2019, 39, 134-141.	2.3	18
466	Comparison of Clinical Presentation and Outcomes of Peritonitis in the Elderly and Younger Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2019, 39, 163-168.	2.3	18
467	Availability, Accessibility, and Quality of Conservative Kidney Management Worldwide. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 79-87.	4.5	18
468	Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney. <i>Journal of Nephropathology</i> , 2013, 2, 154-65.	0.2	18

#	ARTICLE	IF	CITATIONS
469	Moraxella nonliquefaciens Septic Arthritis in a Patient Undergoing Hemodialysis. Clinical Infectious Diseases, 1995, 21, 1039-1040.	5.8	17
470	Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. BMC Nephrology, 2008, 9, 8.	1.8	17
471	Phosphorylation of caveolin-1 is anti-apoptotic and promotes cell attachment during oxidative stress of kidney cells. Pathology, 2008, 40, 694-701.	0.6	17
472	Rationale and design of the HEALTHY-CATH trial: A randomised controlled trial of Heparin versus EthAnol Lock THERapY for the prevention of Catheter Associated infecTion in Haemodialysis patients. BMC Nephrology, 2009, 10, 23.	1.8	17
473	Effect of <i>Astragalus membranaceus</i> and <i>Angelica sinensis</i> combined with Enalapril in rats with obstructive uropathy. Phytotherapy Research, 2010, 24, 875-884.	5.8	17
474	Renal cell carcinoma: Resistance to therapy, role of apoptosis, and the prognostic and therapeutic target potential of TRAF proteins. Medical Hypotheses, 2012, 78, 330-336.	1.5	17
475	The effect of lowering salt intake on ambulatory blood pressure to reduce cardiovascular risk in chronic kidney disease (LowSALT CKD study): protocol of a randomized trial. BMC Nephrology, 2012, 13, 137.	1.8	17
476	Effects of Climatic Region on Peritonitis Risk, Microbiology, Treatment, and Outcomes: A Multicenter Registry Study. Peritoneal Dialysis International, 2013, 33, 75-85.	2.3	17
477	Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network. Kidney International, 2014, 85, 23-30.	5.2	17
478	Assessment of current practice and barriers to antimicrobial prophylaxis in peritoneal dialysis patients. Nephrology Dialysis Transplantation, 2016, 31, 619-627.	0.7	17
479	Effects of exercise and lifestyle intervention on oxidative stress in chronic kidney disease. Redox Report, 2017, 22, 127-136.	4.5	17
480	Role of the unfolded protein response in determining the fate of tumor cells and the promise of multi-targeted therapies. Cell Stress and Chaperones, 2018, 23, 317-334.	2.9	17
481	Prevention of peritoneal dialysis-related peritonitis by regular patient retraining via technique inspection or oral education: a randomized controlled trial. Nephrology Dialysis Transplantation, 2020, 35, 676-686.	0.7	17
482	Strategic plan for integrated care of patients with kidney failure. Kidney International, 2020, 98, S117-S134.	5.2	17
483	The Role of Novel Biomarkers of Cardiovascular Disease in Chronic Kidney Disease: Focus on Adiponectin and Leptin. Current Cardiology Reviews, 2008, 4, 287-292.	1.5	17
484	Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease. , 2022, 1, .		17
485	Epstein-Barr virus encephalitis in a renal allograft recipient diagnosed by polymerase chain reaction on cerebrospinal fluid and successfully treated with ganciclovir. Nephrology Dialysis Transplantation, 2001, 16, 197-198.	0.7	16
486	Implementation of the routine reporting of eGFR in Australia and New Zealand. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 23-29.	1.2	16



#	ARTICLE	IF	CITATIONS
487	Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. <i>BMC Nephrology</i> , 2009, 10, 29.	1.8	16
488	Evaluation of limited sampling strategies for total and free prednisolone in adult kidney transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 1243-1252.	1.9	16
489	Weekend Compared with Weekday Presentations of Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2012, 32, 516-524.	2.3	16
490	A limited sampling strategy for the simultaneous estimation of tacrolimus, mycophenolic acid and unbound prednisolone exposure in adult kidney transplant recipients. <i>Nephrology</i> , 2012, 17, 294-299.	1.6	16
491	Expression profiles and functional associations of endogenous androgen receptor and caveolin-1 in prostate cancer cell lines. <i>Prostate</i> , 2014, 74, 478-487.	2.3	16
492	Economic Evaluation of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions Compared With Standard Solutions: A Secondary Analysis of the balANZ Trial. <i>American Journal of Kidney Diseases</i> , 2015, 65, 773-779.	1.9	16
493	Socio-Economic Status and Peritonitis in Australian Non-Indigenous Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2015, 35, 450-459.	2.3	16
494	Predictors of Transfer to Home Hemodialysis after Peritoneal Dialysis Completion. <i>Peritoneal Dialysis International</i> , 2016, 36, 547-554.	2.3	16
495	Moving on: transitioning young people with chronic kidney disease to adult care. <i>Pediatric Nephrology</i> , 2018, 33, 973-983.	1.7	16
496	Dietary n-3 polyunsaturated fatty acid intake and all-cause and cardiovascular mortality in adults on hemodialysis: The DIET-HD multinational cohort study. <i>Clinical Nutrition</i> , 2019, 38, 429-437.	5.0	16
497	A Simple Clinical Tool for Stratifying Risk of Clinically Significant CKD after Nephrectomy: Development and Multinational Validation. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1107-1117.	6.1	16
498	Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9% saline on delayed graft function in deceased donor kidney transplantation. <i>Trials</i> , 2020, 21, 428.	1.6	16
499	Interventions for weight loss in people with chronic kidney disease who are overweight or obese. <i>The Cochrane Library</i> , 2021, 2021, CD013119.	2.8	16
500	Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 59-76.	6.1	16
501	The honeypot study protocol: a randomized controlled trial of exit-site application of medihoney antibacterial wound gel for the prevention of catheter-associated infections in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2009, 29, 303-9.	2.3	16
502	TGF- $\beta$ 1 dissociates human proximal tubule cell growth and Na <sup>+</sup> -H <sup>+</sup> exchange activity. <i>Kidney International</i> , 1998, 53, 1601-1607.	5.2	15
503	Enalaprilat Directly Ameliorates in vitro Cyclosporin Nephrotoxicity in Human Tubulo-Interstitial Cells. <i>Nephron</i> , 2000, 86, 473-481.	1.8	15
504	Deceased donor renal transplantation- does side matter?. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2583-2588.	0.7	15



#	ARTICLE	IF	CITATIONS
505	Is it time to revisit residual renal function in haemodialysis? (Review Article). <i>Nephrology</i> , 2007, 12, 209-217.	1.6	15
506	Do antibiotic levels need to be followed in treating peritoneal dialysis-associated peritonitis?. <i>Seminars in Dialysis</i> , 2011, 24, 445-446.	1.3	15
507	Cardiorespiratory Fitness Is Independently Associated with 25-Hydroxyvitamin D in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 512-518.	4.5	15
508	Measurement of succinyl-carnitine and methylmalonyl-carnitine on dried blood spot by liquid chromatography-tandem mass spectrometry. <i>Clinica Chimica Acta</i> , 2014, 429, 30-33.	1.1	15
509	The Benefit of a Glucose-Sparing PD Therapy on Glycemic Control Measured by Serum Fructosamine in Diabetic Patients in a Randomized, Controlled Trial (IMPENDIA). <i>Nephron</i> , 2015, 129, 233-240.	1.8	15
510	Association of anthropometric measures with kidney disease progression and mortality: a retrospective cohort study of pre-dialysis chronic kidney disease patients referred to a specialist renal service. <i>BMC Nephrology</i> , 2016, 17, 74.	1.8	15
511	Teaching peritoneal dialysis in Australia: An opportunity for improvement. <i>Nephrology</i> , 2018, 23, 259-263.	1.6	15
512	Predictors of new-onset chronic kidney disease in patients managed surgically for T1a renal cell carcinoma: An Australian population-based analysis. <i>Journal of Surgical Oncology</i> , 2018, 117, 1597-1610.	1.7	15
513	Vitamin D deficiency and treatment versus risk of infection in end-stage renal disease patients under dialysis: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 146-156.	0.7	15
514	Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study. <i>BMC Nephrology</i> , 2019, 20, 417.	1.8	15
515	Perioperative outcomes and risk assessment in dialysis patients: current knowledge and future directions. <i>Internal Medicine Journal</i> , 2019, 49, 702-710.	0.8	15
516	Health disparities in access to kidney replacement therapy amongst children and adolescents with end-stage kidney disease in low- and lower-middle-income countries. <i>Kidney International</i> , 2020, 97, 463-465.	5.2	15
517	Patient-Reported Gastrointestinal Symptoms and the Association With Quality of Life Following Kidney Transplantation. <i>Kidney International Reports</i> , 2021, 6, 138-145.	0.8	15
518	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Africa. <i>Kidney International Supplements</i> , 2021, 11, e11-e23.	14.2	15
519	Urgent-start peritoneal dialysis versus haemodialysis for people with chronic kidney disease. <i>The Cochrane Library</i> , 2021, 2021, CD012899.	2.8	15
520	Epidemiology and Outcomes of Acute Kidney Diseases: A Comparative Analysis. <i>American Journal of Nephrology</i> , 2021, 52, 342-350.	3.1	15
521	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2021, 52, 827-836.	3.1	15
522	Global proteinuria guidelines: are we nearly there yet?. <i>Clinical Biochemist Reviews</i> , 2011, 32, 89-95.	3.3	15

#	ARTICLE	IF	CITATIONS
523	Incremental Versus Standard (Full-Dose) Peritoneal Dialysis. <i>Kidney International Reports</i> , 2022, 7, 165-176.	0.8	15
524	PATIENT MANAGEMENT BY CYCLOSPORINE C2 MONITORING: NOT ENOUGH SCIENCE YET TO JUSTIFY THE PRACTICE. <i>Transplantation</i> , 2003, 75, 1917-1918.	1.0	14
525	High membrane transport status on peritoneal dialysis is not associated with reduced survival following transfer to haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3005-3012.	0.7	14
526	The Role of Monitoring Gentamicin Levels in Patients with Gram-Negative Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2014, 34, 219-226.	2.3	14
527	The Effect of Exit-Site Antibacterial Honey versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the HoneyPot Trial. <i>Peritoneal Dialysis International</i> , 2015, 35, 712-721.	2.3	14
528	The stress response of human proximal tubule cells to cadmium involves up-regulation of haemoxygenase 1 and metallothionein but not cytochrome P450 enzymes. <i>Toxicology Letters</i> , 2016, 249, 5-14.	0.8	14
529	Patterns of oral disease in adults with chronic kidney disease treated with hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1647-1653.	0.7	14
530	Association of Socio-Economic Position with Technique Failure and Mortality in Australian Non-Indigenous Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2017, 37, 397-406.	2.3	14
531	Periodontitis and early mortality among adults treated with hemodialysis: a multinational propensity-matched cohort study. <i>BMC Nephrology</i> , 2017, 18, 166.	1.8	14
532	The SIESTA Trial: A Randomized Study Investigating the Efficacy, Safety, and Tolerability of Acupressure versus Sham Therapy for Improving Sleep Quality in Patients with End-Stage Kidney Disease on Hemodialysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-10.	1.2	14
533	Principles and strategies for involving patients in research in chronic kidney disease: report from national workshops. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1585-1594.	0.7	14
534	Transplant associated infections—The role of the gastrointestinal microbiota and potential therapeutic options. <i>Nephrology</i> , 2020, 25, 5-13.	1.6	14
535	Patient and caregiver perspectives on burnout in peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2021, 41, 484-493.	2.3	14
536	Effect of patient- and center-level characteristics on uptake of home dialysis in Australia and New Zealand: a multicenter registry analysis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1938-1949.	0.7	14
537	Bupi Yishen Formula Versus Losartan for Non-Diabetic Stage 4 Chronic Kidney Disease: A Randomized Controlled Trial. <i>Frontiers in Pharmacology</i> , 2020, 11, 627185.	3.5	14
538	Catheter type, placement and insertion techniques for preventing catheter-related infections in chronic peritoneal dialysis patients. <i>The Cochrane Library</i> , 2019, 2019, CD004680.	2.8	14
539	A single-centre experience of post-renal transplant lymphoproliferative disorder. <i>Transplant International</i> , 2003, 16, 529-536.	1.6	14
540	Diet Quality and Protein-Bound Uraemic Toxins: Investigation of Novel Risk Factors and the Role of Microbiome in Chronic Kidney Disease. , 2022, 32, 542-551.		14

#	ARTICLE	IF	CITATIONS
541	Variation in Peritoneal Dialysis Time on Therapy by Country. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 861-871.	4.5	14
542	Insulin-like growth factor I stimulates apical sodium/hydrogen exchange in human proximal tubule cells. <i>American Journal of Physiology - Renal Physiology</i> , 1997, 272, F484-F490.	2.7	13
543	Serum Leptin Correlates with Fat Mass but not Dietary Energy Intake in Continuous Ambulatory Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 1998, 18, 569-575.	2.3	13
544	Severe hypokalaemia secondary to dicloxacillin. <i>Internal Medicine Journal</i> , 2002, 32, 357-358.	0.8	13
545	Silibinin inhibits renal cell carcinoma via mechanisms that are independent of insulin-like growth factor-binding protein 3. <i>BJU International</i> , 2007, 99, 454-460.	2.5	13
546	Inhibition of nuclear factor kappa B attenuates tumour progression in an animal model of renal cell carcinoma. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1462-1474.	0.7	13
547	Multimodality vascular imaging in CKD: divergence of risk between measured parameters. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 1004-1012.	0.7	13
548	Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1774-1779.	0.7	13
549	Global capacity for clinical research in nephrology: a survey by the International Society of Nephrology. <i>Kidney International Supplements</i> , 2018, 8, 82-89.	14.2	13
550	Omega-3 Polyunsaturated Fatty Acid Supplementation to Prevent Arteriovenous Fistula and Graft Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>American Journal of Kidney Diseases</i> , 2018, 72, 50-61.	1.9	13
551	End-Stage Kidney Disease following Surgical Management of Kidney Cancer. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1641-1648.	4.5	13
552	Estimating risk of encapsulating peritoneal sclerosis accounting for the competing risk of death. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1585-1591.	0.7	13
553	Incremental and twice weekly haemodialysis in Australia and New Zealand. <i>Nephrology</i> , 2019, 24, 1172-1178.	1.6	13
554	Risk factors for major adverse kidney events in the first year after acute kidney injury. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 556-563.	2.9	13
555	A genome-wide association study suggests correlations of common genetic variants with peritoneal solute transfer rates in patients with kidney failure receiving peritoneal dialysis. <i>Kidney International</i> , 2021, 100, 1101-1111.	5.2	13
556	Indoxyl sulphate and p-cresyl sulphate: therapeutically modifiable nephrovascular toxins. <i>OA Nephrology</i> , 2013, 1, .	0.2	13
557	Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. <i>Clinical Biochemist Reviews</i> , 2005, 26, 81-6.	3.3	13
558	Efficacy of Potassium Supplementation in Hypokalemic Patients Receiving Peritoneal Dialysis: A Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2022, 80, 580-588.e1.	1.9	13

#	ARTICLE	IF	CITATIONS
559	Monitoring of Extracellular and Total Body Water during Haemodialysis Using Multifrequency Bio-Electrical Impedance Analysis. <i>Kidney and Blood Pressure Research</i> , 1996, 19, 94-99.	2.0	12
560	Non-invasive, optical measurement of absolute blood volume in hemodialysis patients. <i>Kidney International</i> , 1996, 49, 255-260.	5.2	12
561	Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas. <i>International Journal of Urology</i> , 2005, 12, 17-28.	1.0	12
562	Comparative Analysis of Caspase Activation and Apoptosis in Renal Tubular Epithelial Cells and Renal Cell Carcinomas. <i>Nephron Experimental Nephrology</i> , 2005, 99, e112-e120.	2.2	12
563	Expression of apoptotic tumour necrosis factor receptor-associated factor, caspase recruitment domain and cell death-inducing DFF45 effector genes in therapy-treated renal cell carcinoma. <i>Nephrology</i> , 2009, 14, 205-212.	1.6	12
564	The Roots of Social Dominance: Aggression, Prosocial Behavior, and Social Interdependence. <i>Journal of Educational Research</i> , 2011, 104, 442-454.	1.6	12
565	Magnesium nebulization utilization in management of pediatric asthma (MagNUM PA) trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 261.	1.6	12
566	Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial. <i>PLoS ONE</i> , 2017, 12, e0172735.	2.5	12
567	Outcomes of <i>Acinetobacter</i> Peritonitis in Peritoneal Dialysis Patients: A Multicenter Registry Analysis. <i>Peritoneal Dialysis International</i> , 2018, 38, 257-265.	2.3	12
568	Differences in peritoneal dialysis technique survival between patients treated with peritoneal dialysis systems from different companies. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1035-1044.	0.7	12
569	Dietary Patterns and Mortality in a Multinational Cohort of Adults Receiving Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2020, 75, 361-372.	1.9	12
570	Postoperative outcomes of kidney transplant recipients undergoing non-transplant-related elective surgery: a systematic review and meta-analysis. <i>BMC Nephrology</i> , 2020, 21, 365.	1.8	12
571	Association of Local Unit Sampling and Microbiology Laboratory Culture Practices With the Ability to Identify Causative Pathogens in Peritoneal Dialysis-Associated Peritonitis in Thailand. <i>Kidney International Reports</i> , 2021, 6, 1118-1129.	0.8	12
572	Urgent-start peritoneal dialysis versus conventional-start peritoneal dialysis for people with chronic kidney disease. <i>The Cochrane Library</i> , 2020, 12, CD012913.	2.8	12
573	Perspectives on mental health among patients receiving dialysis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1317-1325.	0.7	12
574	Automated reporting of GFR—coming soon to a laboratory near you!. <i>Australian Family Physician</i> , 2005, 34, 925-31.	0.5	12
575	Predictors of renal recovery in Australian and New Zealand end-stage renal failure patients treated with peritoneal dialysis. <i>Peritoneal Dialysis International</i> , 2007, 27, 184-91.	2.3	12
576	Mortality Trends After Transfer From Peritoneal Dialysis to Hemodialysis. <i>Kidney International Reports</i> , 2022, 7, 1062-1073.	0.8	12

#	ARTICLE	IF	CITATIONS
577	A peritoneal dialysis patient with fatal culture-negative peritonitis. Case Discussion. <i>Nephrology</i> , 2003, 8, 49-55.	1.6	11
578	Derivation and validation of a disease-specific risk score for cardiac risk stratification in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2097-2104.	0.7	11
579	Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2178-2185.	0.7	11
580	Intravenous versus oral iron supplementation for correction of post-transplant anaemia in renal transplant patients. <i>BMC Nephrology</i> , 2009, 10, 14.	1.8	11
581	Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD?. <i>Nephrology</i> , 2011, 16, 144-153.	1.6	11
582	Predictors of Vitamin D Status in Predialysis Chronic Kidney Disease Patients: A Cross-sectional Analysis in a High Ultraviolet Climate. , 2012, 22, 400-408.		11
583	Home versus in-centre haemodialysis for end-stage kidney disease. <i>The Cochrane Library</i> , 2014, 2014, CD009535.	2.8	11
584	Association between GFR Estimated by Multiple Methods at Dialysis Commencement and Patient Survival. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 135-142.	4.5	11
585	APPETITE PREDICTS INTAKE AND NUTRITIONAL STATUS IN PATIENTS RECEIVING PERITONEAL DIALYSIS. <i>Journal of Renal Care</i> , 2016, 42, 123-131.	1.2	11
586	Association between serum hepcidin and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. <i>Nephrology</i> , 2017, 22, 548-554.	1.6	11
587	Intraperitoneal Vancomycin Plus Either Oral Moxifloxacin or Intraperitoneal Ceftazidime for the Treatment of Peritoneal Dialysis-Related Peritonitis: A Randomized Controlled Pilot Study. <i>American Journal of Kidney Diseases</i> , 2017, 70, 30-37.	1.9	11
588	EARLY PERITONITIS AND ITS OUTCOME IN INCIDENT PERITONEAL DIALYSIS PATIENTS. <i>Peritoneal Dialysis International</i> , 2017, , pdi.2017.00029.	2.3	11
589	Is renal tubular cadmium toxicity clinically relevant?. <i>CKJ: Clinical Kidney Journal</i> , 2018, 11, 681-687.	2.9	11
590	Disparities in end-stage kidney disease care for children: a global survey. <i>Kidney International</i> , 2020, 98, 527-532.	5.2	11
591	Patient-led identification and prioritization of exercise interventions for fatigue on dialysis: a workshop report. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 831-839.	2.9	11
592	National and international kidney failure registries: characteristics, commonalities, and contrasts. <i>Kidney International</i> , 2022, 101, 23-35.	5.2	11
593	Oral versus Intravenous Iron Supplementation in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2001, 21, 231-235.	2.3	10
594	Intravenous versus Oral Iron Supplementation in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2007, 27, 255-260.	2.3	10

#	ARTICLE	IF	CITATIONS
595	Automated reporting of eGFR: a useful tool for identifying and managing kidney disease. Medical Journal of Australia, 2009, 190, 200-203.	1.7	10
596	Life-threatening adenovirus infection in a kidney transplant recipient. CKJ: Clinical Kidney Journal, 2009, 2, 250-253.	2.9	10
597	Cardiac and vascular structure and function parameters do not improve with alternate nightly home hemodialysis: An interventional cohort study. BMC Nephrology, 2011, 12, 51.	1.8	10
598	COGNITIVE-HD study: protocol of an observational study of neurocognitive functioning and association with clinical outcomes in adults with end-stage kidney disease treated with haemodialysis. BMJ Open, 2015, 5, e009328.	1.9	10
599	Baseline characteristics of the omega-3 fatty acids (fish oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVORED) study. Nephrology, 2016, 21, 217-228.	1.6	10
600	N-acetyl-cysteine increases cellular dysfunction in progressive chronic kidney damage after acute kidney injury by dampening endogenous antioxidant responses. American Journal of Physiology - Renal Physiology, 2018, 314, F956-F968.	2.7	10
601	Intraperitoneal Cefepime Monotherapy Versus Combination Therapy of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-Associated Peritonitis: A Multicenter, Open-Label, Noninferiority, Randomized, Controlled Trial. American Journal of Kidney Diseases, 2019, 74, 601-609.	1.9	10
602	Impending challenges of the burden of end-stage kidney disease in Australia. Medical Journal of Australia, 2019, 211, 374.	1.7	10
603	Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. American Journal of Kidney Diseases, 2020, 76, 109-120.	1.9	10
604	Associations between diabetes and sex with peritoneal dialysis technique and patient survival: Results from the Australia and New Zealand Dialysis and Transplant Registry cohort study. Peritoneal Dialysis International, 2021, 41, 57-68.	2.3	10
605	Effect of a medium cutoff dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis. Hemodialysis International, 2021, 25, 322-332.	0.9	10
606	Impact of deceased donor with acute kidney injury on subsequent kidney transplant outcomes: an ANZDATA registry analysis. PLoS ONE, 2021, 16, e0249000.	2.5	10
607	Implementation of PDOPPS in a middle-income country: Early lessons from Thailand. Peritoneal Dialysis International, 2021, , 089686082199395.	2.3	10
608	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Latin America. Kidney International Supplements, 2021, 11, e35-e46.	14.2	10
609	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in South Asia. Kidney International Supplements, 2021, 11, e97-e105.	14.2	10
610	International Society of Nephrology Global Kidney Health Atlas: structures, organization and services for the management of kidney failure in North and East Asia. Kidney International Supplements, 2021, 11, e77-e85.	14.2	10
611	The case for increased peritoneal dialysis utilization in low- and lower-middle-income countries. Nephrology, 2022, 27, 391-403.	1.6	10
612	Durable and high rates of remission following chemotherapy in posttransplantation lymphoproliferative disorders after renal transplantation. Transplantation Proceedings, 2003, 35, 256-257.	0.6	9



#	ARTICLE	IF	CITATIONS
613	Clinicians' attitudes to clinical practice guidelines. Medical Journal of Australia, 2003, 178, 354-355.	1.7	9
614	Validation of a nomogram for predicting the likelihood of delayed graft function in Australian adult deceased donor renal transplant recipients. Nephrology, 2006, 11, 78-79.	1.6	9
615	Change in live donor characteristics over the last 25 years: A single centre experience. Nephrology, 2008, 13, 646-650.	1.6	9
616	Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	9
617	HMG CoA reductase inhibitors (statins) for dialysis patients. , 2009, , CD004289.		9
618	The HoneyPot Randomized Controlled Trial Statistical Analysis Plan. Peritoneal Dialysis International, 2013, 33, 426-435.	2.3	9
619	Does the use of neutral pH, low glucose degradation product peritoneal dialysis fluids lead to better patient outcomes?. Current Opinion in Nephrology and Hypertension, 2014, 23, 192-197.	2.0	9
620	HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Sao Paulo Medical Journal, 2015, 133, 541-542.	0.9	9
621	Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet?. American Journal of Kidney Diseases, 2018, 72, 776-778.	1.9	9
622	The Relationship between Body Mass Index and Organism-Specific Peritonitis. Peritoneal Dialysis International, 2018, 38, 206-214.	2.3	9
623	Patient and caregiver perspectives on sleep in dialysis. Journal of Sleep Research, 2021, 30, e13221.	3.2	9
624	Patients' experiences of transitioning between different renal replacement therapy modalities: A qualitative study. Peritoneal Dialysis International, 2020, 40, 548-555.	2.3	9
625	Targeted Education Approach to improve Peritoneal Dialysis Outcomes (TEACH-PD): A feasibility study. Peritoneal Dialysis International, 2020, 40, 153-163.	2.3	9
626	Outcome measures for technique survival reported in peritoneal dialysis: A systematic review. Peritoneal Dialysis International, 2022, 42, 279-287.	2.3	9
627	A Systematic Review of Scope and Consistency of Outcome Measures for Physical Fitness in Chronic Kidney Disease Trials. Kidney International Reports, 2021, 6, 1280-1288.	0.8	9
628	Availability, coverage, and scope of health information systems for kidney care across world countries and regions. Nephrology Dialysis Transplantation, 2021, 37, 159-167.	0.7	9
629	Cardiac biomarkers in dialysis. AIMS Genetics, 2017, 04, 001-020.	1.9	9
630	Patient-reported outcome measures for life participation in peritoneal dialysis: a systematic review. Nephrology Dialysis Transplantation, 2021, 36, 890-901.	0.7	9



#	ARTICLE	IF	CITATIONS
631	Role of protein kinase C and oxidative stress in interleukin-1beta-induced human proximal tubule cell injury and fibrogenesis. <i>Nephrology</i> , 2005, 10, 73-80.	1.6	8
632	Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patients. <i>CKJ: Clinical Kidney Journal</i> , 2009, 2, 508-508.	2.9	8
633	Association between Serum Alkaline Phosphatase and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial. <i>Canadian Journal of Kidney Health and Disease</i> , 2015, 2, 66.	1.1	8
634	The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. <i>Redox Report</i> , 2016, 21, 14-23.	4.5	8
635	Long-term outcomes of end-stage kidney disease for patients with IgA nephropathy: A multicentre registry study. <i>Nephrology</i> , 2016, 21, 387-396.	1.6	8
636	Higher Dialysate Matrix Metalloproteinase-2 Levels are Associated with Peritoneal Membrane Dysfunction. <i>Peritoneal Dialysis International</i> , 2016, 36, 16-25.	2.3	8
637	Centre effects and peritoneal dialysis-related peritonitis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 913-915.	0.7	8
638	Evidence for Biocompatible Peritoneal Dialysis Solutions. <i>Contributions To Nephrology</i> , 2017, 189, 91-101.	1.1	8
639	The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease. <i>Kidney International Supplements</i> , 2017, 7, 130-137.	14.2	8
640	Survival and Quality of Life Impact of a Risk-based Allocation Algorithm for Deceased Donor Kidney Transplantation. <i>Transplantation</i> , 2018, 102, 1530-1537.	1.0	8
641	Associations between Peritoneal Glucose Exposure, Glucose Degradation Product Exposure, and Peritoneal Membrane Transport Characteristics in Peritoneal Dialysis Patients: Secondary Analysis of the ANZ Trial. <i>Peritoneal Dialysis International</i> , 2018, 38, 349-355.	2.3	8
642	Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in REnal Disease (FAVOURED) trial. <i>PLoS ONE</i> , 2019, 14, e0213274.	2.5	8
643	Haemodialysis withdrawal in Australia and New Zealand: a binational registry study. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 669-676.	0.7	8
644	Predictors of Arteriovenous Fistula Failure: A Post Hoc Analysis of the FAVOURED Study. <i>Kidney360</i> , 2020, 1, 1259-1269.	2.1	8
645	Home Hemodialysis and Peritoneal Dialysis Patient and Technique Survival in Canada. <i>Kidney International Reports</i> , 2020, 5, 1965-1973.	0.8	8
646	Perspectives on blood pressure by patients on haemodialysis and peritoneal dialysis. <i>Nephrology</i> , 2021, 26, 62-69.	1.6	8
647	Conducting clinical trials during the COVID-19 pandemic—a collaborative trial network response. <i>Trials</i> , 2021, 22, 278.	1.6	8
648	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in the Middle East. <i>Kidney International Supplements</i> , 2021, 11, e47-e56.	14.2	8

#	ARTICLE	IF	CITATIONS
649	Temporal changes and risk factors for death from early withdrawal within 12 months of dialysis initiation—a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 760-769.	0.7	8
650	Erythropoietin Protects Against Acute Kidney Injury and Failure. <i>The Open Drug Discovery Journal</i> , 2010, 2, 8-17.	0.7	8
651	Rate of decline in residual kidney function pre and post peritoneal dialysis initiation: A post hoc analysis of the IDEAL study. <i>PLoS ONE</i> , 2020, 15, e0242254.	2.5	8
652	Commentary on the 2020 update of the KDOQI clinical practice guideline for nutrition in chronic kidney disease. <i>Nephrology</i> , 2022, 27, 537-540.	1.6	8
653	In vitro effects of simvastatin on tubulointerstitial cells in a human model of cyclosporin nephrotoxicity. <i>American Journal of Physiology - Renal Physiology</i> , 1999, 276, F467-F475.	2.7	7
654	Increases in peritoneal small solute transport in the first month of peritoneal dialysis predict technique survival. <i>Nephrology</i> , 2004, 9, 341-347.	1.6	7
655	Baseline and time-averaged fluid removal affect technique survival in peritoneal dialysis in a non-linear fashion. <i>Nephrology</i> , 2007, 12, 218-223.	1.6	7
656	How to conduct a randomized trial. <i>Nephrology</i> , 2010, 15, 740-746.	1.6	7
657	End-stage kidney disease due to haemolytic uraemic syndrome—outcomes in 241 consecutive ANZDATA registry cases. <i>BMC Nephrology</i> , 2012, 13, 164.	1.8	7
658	Fibronectin and transforming growth factor beta contribute to erythropoietin resistance and maladaptive cardiac hypertrophy. <i>Biochemical and Biophysical Research Communications</i> , 2014, 444, 332-337.	2.1	7
659	Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The BAL Anz Trial. <i>Peritoneal Dialysis International</i> , 2015, 35, 159-171.	2.3	7
660	Comparison of Topical Chlorhexidine and Mupirocin for the Prevention of Exit-Site Infection in Incident Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2017, 37, 266-272.	2.3	7
661	Impact of Diabetes Mellitus on the Association of Vascular Disease Before Transplantation With Long-term Transplant and Patient Outcomes After Kidney Transplantation: A Population Cohort Study. <i>American Journal of Kidney Diseases</i> , 2018, 71, 102-111.	1.9	7
662	Nephrology in the Oceania—South East Asia region: perspectives and challenges. <i>Kidney International</i> , 2018, 94, 465-470.	5.2	7
663	Infectious Complications Following Kidney Transplantation—A Focus on Hepatitis C Infection, Cytomegalovirus Infection and Novel Developments in the Gut Microbiota. <i>Medicina (Lithuania)</i> , 2019, 55, 672.	2.0	7
664	Long-term outcomes of patients with end-stage kidney disease due to membranous nephropathy: A cohort study using the Australia and New Zealand Dialysis and Transplant Registry. <i>PLoS ONE</i> , 2019, 14, e0221531.	2.5	7
665	Catheter Type, Placement, and Insertion Techniques for Preventing Catheter-Related Infections in Maintenance Peritoneal Dialysis Patients: Summary of a Cochrane Review. <i>American Journal of Kidney Diseases</i> , 2019, 74, 703-705.	1.9	7
666	GRP78 expression in tumor and perinephric adipose tissue is not an optimal risk stratification marker for clear cell renal cell carcinoma. <i>PLoS ONE</i> , 2019, 14, e0210246.	2.5	7

#	ARTICLE	IF	CITATIONS
667	PAR2 Activation on Human Kidney Tubular Epithelial Cells Induces Tissue Factor Synthesis, That Enhances Blood Clotting. <i>Frontiers in Physiology</i> , 2021, 12, 615428.	2.8	7
668	T-Cell Expression and Release of Kidney Injury Molecule-1 in Response to Glucose Variations Initiates Kidney Injury in Early Diabetes. <i>Diabetes</i> , 2021, 70, 1754-1766.	0.6	7
669	Postoperative outcomes after bariatric surgery in patients on chronic dialysis: A systematic review and meta-analysis. <i>Obesity Research and Clinical Practice</i> , 2021, 15, 473-484.	1.8	7
670	Perspectives on ability to work from patientsâ€™ receiving dialysis and caregivers: analysis of data from the global SONG initiative. <i>Journal of Nephrology</i> , 2022, 35, 255-266.	2.0	7
671	Development of an international Delphi survey to establish core outcome domains for trials in adults with glomerular disease. <i>Kidney International</i> , 2021, 100, 881-893.	5.2	7
672	Availability and Affordability of Kidney Health Laboratory Tests around the Globe. <i>American Journal of Nephrology</i> , 2020, 51, 959-965.	3.1	7
673	Stability and compatibility of antibiotics in peritoneal dialysis solutions. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1071-1078.	2.9	7
674	Assisted peritoneal dialysis performed by caregivers and its association with patient outcomes. <i>Peritoneal Dialysis International</i> , 2022, 42, 602-614.	2.3	7
675	Establishing a core outcome measure for life participation in patients receiving peritoneal dialysis: A Standardised Outcomes in Nephrologyâ€™ Peritoneal Dialysis consensus workshop report. <i>Peritoneal Dialysis International</i> , 2022, 42, 562-570.	2.3	7
676	Randomized Study of Urgent-Start Peritoneal Dialysis Versus Urgent-Start Temporary Hemodialysis in Patients Transitioning to Kidney Failure. <i>Kidney International Reports</i> , 2022, 7, 1866-1877.	0.8	7
677	Physiological changes in extracellular sodium directly control human proximal tubule growth and transport. <i>Pflugers Archiv European Journal of Physiology</i> , 1997, 435, 211-218.	2.8	6
678	Growth factors in progressive renal disease. <i>Nephrology</i> , 2000, 5, 251-261.	1.6	6
679	Peritoneal Homocysteine Clearance is Inefficient in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2000, 20, 766-771.	2.3	6
680	Administration of erythropoietin and its derivatives in renal disease: Advantages, mechanisms and concerns. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2007, 4, 79-84.	0.5	6
681	Central obesity is common in renal transplant recipients and is associated with increased prevalence of cardiovascular risk factors. <i>Nutrition and Dietetics</i> , 2007, 64, 200-206.	1.8	6
682	Opinions on the Content and Effects of Clinical Practice Guidelines for CKD: A Survey of Nephrologists in Australia and New Zealand. <i>American Journal of Kidney Diseases</i> , 2009, 53, 1082-1090.	1.9	6
683	Review article: Addressing risk factors in chronic kidney disease mineral and bone disorder: Can we influence patientâ€™level outcomes?. <i>Nephrology</i> , 2009, 14, 416-427.	1.6	6
684	Effect of Dialysis Modality on Survival of Hepatitis C-Infected ESRF Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2657-2661.	4.5	6

#	ARTICLE	IF	CITATIONS
685	Interventions for erythropoietin-resistant anaemia in dialysis patients. The Cochrane Library, 2013, , CD006861.	2.8	6
686	Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways. Biochemical and Biophysical Research Communications, 2016, 473, 47-53.	2.1	6
687	Pro: Meta-analysis: the case<i>for</i>. Nephrology Dialysis Transplantation, 2016, 31, 875-880.	0.7	6
688	Association between Peritoneal Glucose Exposure and Peritonitis in Peritoneal Dialysis Patients: TheBalANZ Trial. Peritoneal Dialysis International, 2017, 37, 407-413.	2.3	6
689	Interventions for weight loss in people with chronic kidney disease who are overweight or obese. The Cochrane Library, 0, , .	2.8	6
690	Multicenter registry analysis comparing survival on home hemodialysis and kidney transplant recipients in Australia and New Zealand. Nephrology Dialysis Transplantation, 2020, 36, 1937-1946.	0.7	6
691	Pathophysiology and significance of natriuretic peptides in patients with end-stage kidney disease. Clinical Biochemistry, 2020, 83, 1-11.	1.9	6
692	Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 346-352.	2.0	6
693	Self-Reported Physical Activity and Survival in Adults Treated With Hemodialysis: A DIET-HD Cohort Study. Kidney International Reports, 2021, 6, 3014-3025.	0.8	6
694	Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients. Transplantation, 2003, 76, 619.	1.0	5
695	Use of estimated glomerular filtration rate to assess level of kidney function. Nephrology, 2005, 10, S140-S156.	1.6	5
696	A Randomized Controlled Trial to Determine Whether Treatment with a Neutral pH, Low Glucose Degradation Product Dialysate (Balance) Prolongs Residual Renal Function in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2006, 26, 112-112.	2.3	5
697	How to design a randomized controlled trial. Nephrology, 2010, 15, 732-739.	1.6	5
698	Is Female Sex Really a Risk Factor for Infectious Death in Peritoneal Dialysis?. Peritoneal Dialysis International, 2013, 33, 475-478.	2.3	5
699	Honey in the Prevention and Treatment of Infection in the CKD Population: A Narrative Review. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-8.	1.2	5
700	Effect of centreâ€and patientâ€related factors on uptake of haemodiafiltration in Australia and New Zealand: A cohort study using ANZDATA. Nephrology, 2020, 25, 63-72.	1.6	5
701	Effectiveness and safety of pneumococcal vaccines used alone or combined with influenza vaccination in dialysis patients: A systematic review and meta-analysis. Vaccine, 2020, 38, 7422-7432.	3.8	5
702	â€A sword of Damoclesâ€™: patient and caregiver beliefs, attitudes and perspectives on presymptomatic testing for autosomal dominant polycystic kidney disease: a focus group study. BMJ Open, 2020, 10, e038005.	1.9	5

#	ARTICLE	IF	CITATIONS
703	Novel trial strategies to enhance the relevance, efficiency, effectiveness, and impact of nephrology research. <i>Kidney International</i> , 2020, 98, 572-578.	5.2	5
704	“Can I go to Glasgow?” Learnings from patient involvement at the 17th Congress of the International Society for Peritoneal Dialysis (ISPD). <i>Peritoneal Dialysis International</i> , 2020, 40, 12-25.	2.3	5
705	Comparison of outcomes of urgent-start and conventional-start peritoneal dialysis: a single-centre experience. <i>International Urology and Nephrology</i> , 2021, 53, 583-590.	1.4	5
706	Association between self-reported appetite and clinical outcomes of peritoneal dialysis patients: Findings from a low middle-income country. <i>Nephrology</i> , 2021, 26, 454-462.	1.6	5
707	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Eastern and Central Europe. <i>Kidney International Supplements</i> , 2021, 11, e24-e34.	14.2	5
708	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Oceania and South East Asia. <i>Kidney International Supplements</i> , 2021, 11, e86-e96.	14.2	5
709	Managing the cardiovascular complications of chronic kidney disease. <i>Australian Prescriber</i> , 2008, 31, 154-158.	1.0	5
710	Chronic kidney disease—management update. <i>Australian Family Physician</i> , 2005, 34, 915-23.	0.5	5
711	Prebiotic Supplementation in Kidney Transplant Recipients for Preventing Infections and Gastrointestinal Upset: A Randomized Controlled Feasibility Study. , 2022, 32, 718-725.		5
712	Predictors and outcomes of peritoneal dialysis-related infections due to filamentous molds (Mycoplasma). <i>PLoS ONE</i> , 2022, 17, e0268823.	2.5	5
713	Severe Irreversible Proximal Renal Tubular Acidosis and Azotaemia Secondary to Cidofovir. <i>Nephron</i> , 2000, 86, 348-349.	1.8	4
714	FK778: A Powerful Immunosuppressive, But Will It Really be Good for You?. <i>Transplantation</i> , 2004, 78, 7-8.	1.0	4
715	Association of pre-transplant statin use with delayed graft function in kidney transplant recipients. <i>BMC Nephrology</i> , 2012, 13, 111.	1.8	4
716	Factors associated with acutely elevated serum creatinine following radical tumour nephrectomy: the Correlates of Kidney Dysfunction—Tumour Nephrectomy Database study. <i>Translational Andrology and Urology</i> , 2017, 6, 899-909.	1.4	4
717	Practice of Peritoneal Dialysis Catheter Flushing in Australia and New Zealand: Multi-Center Cross-Sectional Survey. <i>Peritoneal Dialysis International</i> , 2018, 38, 98-103.	2.3	4
718	Association between reduced renal function and cardiovascular mortality in patients hospitalized with infection: A multi-center cohort study. <i>European Journal of Internal Medicine</i> , 2018, 57, 32-38.	2.2	4
719	The Power of the Patient Voice: Conducting and Using Qualitative Research to Improve Care and Outcomes in Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2018, 38, 242-245.	2.3	4
720	The effects of oral vitamin D supplementation on the prevention of peritoneal dialysis-related peritonitis: study protocol for a randomized controlled clinical trial. <i>Trials</i> , 2019, 20, 657.	1.6	4

#	ARTICLE	IF	CITATIONS
721	Serum Galactomannan Index for the Rapid Diagnosis of Fungal Peritonitis in Patients With Peritoneal Dialysis. <i>Kidney International Reports</i> , 2020, 5, 530-534.	0.8	4
722	A cost-effective three-dimensional culture platform functionally mimics the adipose tissue microenvironment surrounding the kidney. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 736-742.	2.1	4
723	Perioperative antibiotics for preventing post-surgical site infections in solid organ transplant recipients. <i>The Cochrane Library</i> , 2020, 8, CD013209.	2.8	4
724	Patient and center characteristics associated with kidney transplant outcomes: a binational registry analysis. <i>Transplant International</i> , 2020, 33, 1667-1680.	1.6	4
725	Icodextrin use for peritoneal dialysis in Australia: A cohort study using Australia and New Zealand Dialysis and Transplant Registry. <i>Peritoneal Dialysis International</i> , 2020, 40, 209-219.	2.3	4
726	Characteristics of the gastrointestinal microbiota in paired live kidney donors and recipients. <i>Nephrology</i> , 2021, 26, 471-478.	1.6	4
727	Range and Consistency of Infection Outcomes Reported in Trials Conducted in Kidney Transplant Recipients: A Systematic Review. <i>Transplantation</i> , 2021, 105, 2632-2638.	1.0	4
728	Advanced glycation end products as predictors of renal function in youth with type 1 diabetes. <i>Scientific Reports</i> , 2021, 11, 9422.	3.3	4
729	Recent Clinical Trials of Pharmacologic Cardiovascular Interventions in Patients with Chronic Kidney Disease: An Update. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 12-32.	0.8	4
730	Scope and heterogeneity of outcomes reported in randomized trials in patients receiving peritoneal dialysis. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1817-1825.	2.9	4
731	Identifying new-onset conditions and pre-existing conditions using lookback periods in Australian health administrative datasets. <i>International Journal for Quality in Health Care</i> , 2021, 33, .	1.8	4
732	Prevention of progression of kidney disease - CARI guidelines. <i>Australian Family Physician</i> , 2007, 36, 353.	0.5	4
733	Spiritual well-being and its relationship with patient characteristics and other patient-reported outcomes in peritoneal dialysis patients: Findings from the PDOPPS. <i>Nephrology</i> , 2022, 27, 621-631.	1.6	4
734	Educating primary healthcare providers about kidney disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 133-134.	9.6	4
735	Consumers' Perspectives and Experiences of Prebiotics and Probiotics for Gut Health in Chronic Kidney Disease. , 2023, 33, 116-125.		4
736	Dramatic response of livedoid vasculitis to tissue plasminogen activator (tPA). <i>Australian and New Zealand Journal of Medicine</i> , 1995, 25, 370-371.	0.5	3
737	Metabolism of trideuterated iso-lignoceric acid in rats in Vivo and in human fibroblasts in culture. <i>Lipids</i> , 1999, 34, 943-949.	1.7	3
738	Maintaining clearance in peritoneal dialysis. <i>Nephrology</i> , 2001, 6, 243-249.	1.6	3

#	ARTICLE	IF	CITATIONS
739	Mycophenolate mofetil for treatment of refractory lupus nephritis. Internal Medicine Journal, 2001, 31, 312-312.	0.8	3
740	Atypical Ductal Hyperplasia of the Breast in Young Women: Two Case Reports. Asian Journal of Surgery, 2003, 26, 37-39.	0.4	3
741	Classification of chronic kidney disease based on evaluation of kidney function. Nephrology, 2005, 10, S172-S176.	1.6	3
742	Sevelamer versus calcium-based phosphate binders in chronic kidney disease: what should we conclude from the evidence to date?. Nephrology Dialysis Transplantation, 2009, 24, 2970-2972.	0.7	3
743	Opinions on the content and effects of the Caring for Australasians with Renal Impairment (CARI) Guidelines: A survey of renal nurses and comparison with the opinions of nephrologists in Australasia. Nephrology, 2010, 15, 48-53.	1.6	3
744	Trials (and Tribulations) of Biocompatible Peritoneal Dialysis Fluids. Peritoneal Dialysis International, 2012, 32, 247-251.	2.3	3
745	A Differential Impact of Mycophenolic Acid, Prednisolone, and Tacrolimus Exposure on sCD30 Levels in Adult Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2013, 35, 240-245.	2.0	3
746	Peritoneal Dialysis Solutions. , 2016, , .		3
747	Temporal Changes in Deceased Kidney Donor Characteristics in Australia. Transplantation Direct, 2016, 2, e112.	1.6	3
748	Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions. Peritoneal Dialysis International, 2016, 36, 146-153.	2.3	3
749	Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in REnal Disease (FAVOURED) study. Nephrology, 2017, 22, 823-824.	1.6	3
750	Representativeness of Honeypot Trial Participants to Australasian PD Patients. Peritoneal Dialysis International, 2017, 37, 516-522.	2.3	3
751	Early Onset Peritoneal Dialysis-Related Peritonitis. Journal of Clinical & Experimental Nephrology, 2017, 2, .	0.1	3
752	Automatic reporting of estimated glomerular filtration rate in Australia turns 13: re-examining the impact. Medical Journal of Australia, 2018, 209, 244-245.	1.7	3
753	PD Solutions and Peritoneal Health. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1455-1457.	4.5	3
754	The Role of Oxidative Stress and Systemic Inflammation in Kidney Disease and Its Associated Cardiovascular Risk. , 0, , .		3
755	Impact of an emergency department-run clinical decision unit on access block, ambulance ramping and National Emergency Access Target. EMA - Emergency Medicine Australasia, 2019, 31, 200-204.	1.1	3
756	Protease-activated receptor 2 does not contribute to renal inflammation or fibrosis in the obstructed kidney. Nephrology, 2019, 24, 983-991.	1.6	3



#	ARTICLE	IF	CITATIONS
757	Capacity of Kidney Care in Canada: Identifying Barriers and Opportunities. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811987054.	1.1	3
758	Allograft failure in kidney transplant recipients who developed kidney failure secondary to ANCA-associated vasculitis. Clinical Transplantation, 2021, 35, e14235.	1.6	3
759	Expression of protease activated receptor-2 is reduced in renal cell carcinoma biopsies and cell lines. PLoS ONE, 2021, 16, e0248983.	2.5	3
760	Recent evidence on the effect of treatment of metabolic acid on the progression of kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 467-473.	2.0	3
761	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Newly Independent States and Russia. Kidney International Supplements, 2021, 11, e57-e65.	14.2	3
762	Global variation in kidney care: national and regional differences in the care and management of patients with kidney failure. Kidney International Supplements, 2021, 11, e1-e3.	14.2	3
763	International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in North America and the Caribbean. Kidney International Supplements, 2021, 11, e66-e76.	14.2	3
764	Patient navigator programmes for children and adolescents with chronic diseases. The Cochrane Library, 2021, 2021, .	2.8	3
765	Perioperative antibiotics for preventing post-surgical site infections in solid organ transplant recipients. The Cochrane Library, 0, , .	2.8	3
766	MANAGEMENT OF FUNCTIONING THYROID CANCER. Medical Journal of Australia, 1969, 1, 372-378.	1.7	3
767	How do patients and their family members experience the transition from peritoneal dialysis to in-centre haemodialysis? A multisite qualitative study in England and Australia. Peritoneal Dialysis International, 2022, 42, 297-304.	2.3	3
768	Impact of COVID-19 on the worsening crisis of chronic kidney disease: the imperative to fund early detection is now. Internal Medicine Journal, 2022, 52, 680-682.	0.8	3
769	Global eHealth capacity: secondary analysis of WHO data on eHealth and implications for kidney care delivery in low-resource settings. BMJ Open, 2022, 12, e055658.	1.9	3
770	Clinical appearance of a post-transplant lymphoma following G-CSF therapy. Nephrology Dialysis Transplantation, 1999, 14, 1806-1807.	0.7	2
771	Selection of patients for automated peritoneal dialysis versus continuous ambulatory peritoneal dialysis. Nephrology, 2005, 10, S89-S94.	1.6	2
772	Obliterative bronchiolitis or opportunistic infection? A diagnostic challenge in a renal transplant patient. Nephrology Dialysis Transplantation, 2005, 20, 246-247.	0.7	2
773	Attempting to Build Solid Recommendations on a Shaky Evidence Base. Seminars in Dialysis, 2011, 24, 22-24.	1.3	2
774	Cochrane Review: Nebulized epinephrine for croup in children. Evidence-Based Child Health: A Cochrane Review Journal, 2012, 7, 1311-1354.	2.0	2

#	ARTICLE	IF	CITATIONS
775	Haemodialysis catheter care in practice. <i>Nature Reviews Nephrology</i> , 2014, 10, 131-133.	9.6	2
776	The impact of fibroblast growth factor-23 on the cardiovascular system in chronic kidney disease. <i>Expert Review of Endocrinology and Metabolism</i> , 2015, 10, 565-568.	2.4	2
777	A nephrology guide to reading and using systematic reviews of randomized trials. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 878-884.	0.7	2
778	Daily Home Hemodialysis: Balancing Cardiovascular Benefits With Infectious Harms. <i>American Journal of Kidney Diseases</i> , 2015, 65, 6-8.	1.9	2
779	Carotid extra-medial thickness does not predict adverse cardiovascular outcomes in high-risk adults. <i>Diabetes and Metabolism</i> , 2016, 42, 200-203.	2.9	2
780	Improving Nutrition Research in Nephrology: An Appetite for Change. <i>American Journal of Kidney Diseases</i> , 2017, 69, 558-560.	1.9	2
781	Urgent-start peritoneal dialysis versus haemodialysis for people with chronic kidney disease. <i>The Cochrane Library</i> , 0, , .	2.8	2
782	In Reply to "The Importance of Icodextrin Use for Technique and Patient Survival in Peritoneal Dialysis". <i>American Journal of Kidney Diseases</i> , 2018, 72, 309-310.	1.9	2
783	Cardiovascular Disease in Dialysis Patients. , 0, , .		2
784	FP55 EFFECTS OF FISH OIL SUPPLEMENTATION AND ASPIRIN USE ON NEED FOR ARTERIOVENOUS FISTULA INTERVENTIONS AND CENTRAL VENOUS CATHETERS IN PATIENTS REQUIRING HAEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i227-i227.	0.7	2
785	The Roles of Indoxyl Sulphate and p-Cresyl Sulphate in Patients with Chronic Kidney Disease: A Review of Therapeutic Options. , 0, , .		2
786	Perioperative Care for Kidney Transplant Recipients. , 2019, , .		2
787	Oral mucosal lesions and risk of all-cause and cardiovascular mortality in people treated with long-term haemodialysis: The ORAL-D multinational cohort study. <i>PLoS ONE</i> , 2019, 14, e0218684.	2.5	2
788	A Theory-Driven, Evidence-Based Approach to Implementing the ISPD Syllabus "Patients as Learners". <i>Peritoneal Dialysis International</i> , 2019, 39, 409-413.	2.3	2
789	Early technique failure in peritoneal dialysis patients in a multi-ethnic Asian country. <i>International Urology and Nephrology</i> , 2020, 52, 1987-1994.	1.4	2
790	Chlorhexidine-impregnated sponge dressing for prevention of catheter exit-site infection in peritoneal dialysis patients: a pilot study. <i>International Urology and Nephrology</i> , 2021, 53, 803-812.	1.4	2
791	Barriers to and constraints of acute peritoneal dialysis in acute kidney injury: A nationwide survey. <i>Peritoneal Dialysis International</i> , 2022, 42, 92-95.	2.3	2
792	Center-Effect of Incident Hemodialysis Vascular Access Use: Analysis of a Bi-national Registry. <i>Kidney360</i> , 2021, 2, 674-683.	2.1	2

#	ARTICLE	IF	CITATIONS
793	Dialysis initiation in older persons across centres and over time in Australia and New Zealand. <i>Nephrology</i> , 2021, 26, 613-622.	1.6	2
794	Understanding distribution and variability in care organization and services for the management of kidney care across world regions. <i>Kidney International Supplements</i> , 2021, 11, e4-e10.	14.2	2
795	Renal staffs'™ understanding of patients'™ experiences of transition from peritoneal dialysis to in-centre haemodialysis and their views on service improvement: A multi-site qualitative study in England and Australia. <i>PLoS ONE</i> , 2021, 16, e0254931.	2.5	2
796	PAR2-Induced Tissue Factor Synthesis by Primary Cultures of Human Kidney Tubular Epithelial Cells Is Modified by Glucose Availability. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7532.	4.1	2
797	Socio-economic disparity, access to care and patient-relevant outcomes after kidney allograft failure. <i>Transplant International</i> , 2021, 34, 2329-2340.	1.6	2
798	A focus group study of self-management in patients with glomerular disease.. <i>Kidney International Reports</i> , 2021, 7, 56-67.	0.8	2
799	Representativeness of the PDOPPS cohort compared to the Australian PD population. <i>Peritoneal Dialysis International</i> , 2022, 42, 403-414.	2.3	2
800	Statistical analysis plan for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a randomised controlled trial of the effect of intravenous fluid therapy with balanced crystalloid versus saline on the incidence of delayed graft function in deceased donor kidney transplantation. <i>Trials</i> , 2022, 23, 52.	1.6	2
801	Associations, microbiology and outcomes of pre-training peritoneal dialysis-related peritonitis. <i>Peritoneal Dialysis International</i> , 2023, 43, 173-181.	2.3	2
802	Critically important outcomes for infection in trials in kidney transplantation: An international survey of patients, caregivers, and health professionals. <i>Clinical Transplantation</i> , 2022, 36, e14660.	1.6	2
803	Dialysis Outcomes in a Middle-Income Country: An Updated Comparison of Patient Mortality between Hemodialysis and Peritoneal Dialysis. <i>Blood Purification</i> , 2022, 51, 780-790.	1.8	2
804	A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial. <i>Journal of Vascular Access</i> , 2024, 25, 193-202.	0.9	2
805	Role of insulin-like growth factor binding proteins in human post-nephrectomy proximal tubule cells. <i>Journal of Physiology</i> , 1998, 508, 587-595.	2.9	1
806	Sunshine, sweating, and main d'accoucheur. <i>Lancet, The</i> , 1999, 353, 1492.	13.7	1
807	Treatment of peritoneal dialysis related peritonitis. <i>Australian and New Zealand Journal of Medicine</i> , 2000, 30, 97-97.	0.5	1
808	Chest pain, syncope, and puddings. <i>Lancet, The</i> , 2000, 356, 1322.	13.7	1
809	Monitoring patients on peritoneal dialysis. <i>Nephrology</i> , 2005, 10, S86-S88.	1.6	1
810	Time-Integrated CRP Level Strongly Predicts PD Patient Outcomes - Nice to Know, but what Should we do about It?. <i>Peritoneal Dialysis International</i> , 2005, 25, 234-237.	2.3	1

#	ARTICLE	IF	CITATIONS
811	Chronic kidney disease and automatic reporting of estimated glomerular filtration rate. Medical Journal of Australia, 2006, 184, 476-477.	1.7	1
812	Acute Renal Failure in Patients on Diuretics and/or NSAID, COX-2 inhibitors, ACEI, ARA. Journal of Pharmacy Practice and Research, 2008, 38, 280-282.	0.8	1
813	Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: revised recommendations. Medical Journal of Australia, 2008, 188, 427-430.	1.7	1
814	Estimated glomerular filtration rate: Which equation is best and how should it be used?. Nephrology, 2011, 16, 483-485.	1.6	1
815	Enterococcal Peritonitis in Peritoneal Dialysis: The Danger from Within?. Peritoneal Dialysis International, 2011, 31, 518-521.	2.3	1
816	Introduction to Clinical Answers: Croup. Evidence-Based Child Health: A Cochrane Review Journal, 2012, 7, 883-885.	2.0	1
817	Opponent's comments. Nephrology Dialysis Transplantation, 2016, 31, 885-886.	0.7	1
818	Erythropoietin corrects anaemia and reduces the risk of blood transfusion in people with chronic kidney disease, but has uncertain effects on other patient-level outcomes. Evidence-Based Medicine, 2016, 21, 178-178.	0.6	1
819	Recurrent atypical haemolytic uraemic syndrome post kidney transplant due to aCD46mutation in the setting ofSMARCAL1-mediated inherited kidney disease. Nephrology, 2017, 22, 11-14.	1.6	1
820	Tacrolimus Toxicity due to Biliary Obstruction in a Combined Kidney and Liver Transplant Recipient. Case Reports in Transplantation, 2017, 2017, 1-4.	0.3	1
821	Urgent-start peritoneal dialysis versus conventional-start peritoneal dialysis for people with chronic kidney disease. The Cochrane Library, 2018, , .	2.8	1
822	Pathogenesis and Prevention of Vascular Access Failure. , 2019, , .		1
823	Assessment of Restored Kidney Transplantation Including the Use of Wider Criteria for Accepting Renal Donors After Cancer Excision. Transplantation Direct, 2019, 5, e498.	1.6	1
824	Comparison of graft and patient outcomes following kidney transplantation in extended hour and conventional haemodialysis patients. Nephrology, 2019, 24, 111-120.	1.6	1
825	Assessment of Dietary Sodium Intake Using the Scored Salt Questionnaire in Autosomal Dominant Polycystic Kidney Disease. Nutrients, 2020, 12, 3376.	4.1	1
826	Practice patterns and predictors of outpatient care following acute kidney injury in an Australian healthcare setting. Internal Medicine Journal, 2022, 52, 79-88.	0.8	1
827	Peritoneal dialysis versus haemodialysis for people commencing dialysis. The Cochrane Library, 2020, , .	2.8	1
828	Shetty test in ankle and foot trauma: An emergency department pilot study assessing specificity and sensitivity. EMA - Emergency Medicine Australasia, 2020, 32, 683-686.	1.1	1

#	ARTICLE	IF	CITATIONS
829	Raising the standard of trial registration, conduct, and reporting. <i>Peritoneal Dialysis International</i> , 2020, 40, 112-114.	2.3	1
830	Utility of serum beta-trace protein as a tool for estimating residual kidney function in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , 2021, 41, 226-235.	2.3	1
831	Impact of Peritoneal Dialysis Solutions on Outcomes. , 0, , 500-508.		1
832	Prevention and Treatment of Peritoneal Dialysis-Related Infections. , 0, , 509-532.		1
833	Automated laboratory reporting of estimated glomerular filtration rate: is it good for the health of patients and their doctors?. <i>Biochemia Medica</i> , 0, , 16-28.	2.7	1
834	Australian general practitionersâ€™ current practice for chronic kidney disease (CKD) detection and management. <i>Australasian Medical Journal</i> , 2017, 10, .	0.1	1
835	Sex differences in the likelihood of pre-emptive living donor kidney transplantation, and outcomes after kidney transplantation in children and adolescents. <i>Pediatric Transplantation</i> , 2022, , e14224.	1.0	1
836	Effect of a Hemodialysis Session on Markers of Inflammation and Endotoxin. <i>International Journal of Inflammation</i> , 2022, 2022, 1-7.	1.5	1
837	Evaluating data quality in the Australian and New Zealand dialysis and transplant registry using administrative hospital admission datasets and data-linkage. <i>Health Information Management Journal</i> , 0, , 183335832210977.	1.2	1
838	Vancomycin-resistant enterococci: seek and ye shall find. <i>Medical Journal of Australia</i> , 2000, 172, 42-43.	1.7	0
839	Management of Tenckhoff exit sites. <i>Nephrology</i> , 2002, 7, S62-S63.	1.6	0
840	BODY MASS INDEX AND RENAL TRANSPLANT OUTCOMES. <i>Transplantation</i> , 2003, 76, 1651.	1.0	0
841	Response: Iron Therapy in Renal Transplant Recipients. <i>Transplantation</i> , 2004, 78, 1240.	1.0	0
842	Optimizing small solute clearances in peritoneal dialysis. <i>Nephrology</i> , 2005, 10, S95-S103.	1.6	0
843	Peritoneal transport and ultrafiltration. <i>Nephrology</i> , 2005, 10, S104-S107.	1.6	0
844	43 Large animal models of renal warm ischaemia/reperfusion injury. Comparison of dog versus pig. <i>BJU International</i> , 2006, 97, 12-13.	2.5	0
845	44 Erythropoietin reduces functional impairment following renal ischaemia/ reperfusion injury in pigs. <i>BJU International</i> , 2006, 97, 13-13.	2.5	0
846	Re: Croup in the paediatric emergency department. <i>Paediatrics and Child Health</i> , 2007, , .	0.6	0

#	ARTICLE	IF	CITATIONS
847	Honey has potential uses in patients with chronic kidney disease but few studies have been undertaken. Focus on Alternative and Complementary Therapies, 2015, 20, 170-171.	0.1	0
848	SP435VARIATION IN THE TREATMENT AND PREVENTION OF PERITONEAL DIALYSIS RELATED INFECTIONS: PRELIMINARY RESULTS FROM THE PERITONEAL DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (PDOPPS). Nephrology Dialysis Transplantation, 2016, 31, i236-i237.	0.7	0
849	SP444INTERNATIONAL VARIATIONS IN THE EXPERIENCE OF PATIENTS ON PERITONEAL DIALYSIS (PD) IN THE PERITONEAL DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (PDOPPS). Nephrology Dialysis Transplantation, 2016, 31, i239-i240.	0.7	0
850	An update on bone imaging and markers in chronic kidney disease. Expert Review of Endocrinology and Metabolism, 2016, 11, 455-466.	2.4	0
851	Opponent's comments. Nephrology Dialysis Transplantation, 2016, 31, 524-524.	0.7	0
852	Biological variation of high sensitivity cardiac troponin-T in stable dialysis patients: implications for clinical practice. Clinical Chemistry and Laboratory Medicine, 2016, 54, e149-50.	2.3	0
853	Administration of erythropoiesis-stimulating agents in patients undergoing haemodialysis: A time and motion study. Journal of Renal Care, 2017, 43, 219-225.	1.2	0
854	SP383ASSOCIATION BETWEEN EGFR AND CARDIOVASCULAR MORTALITY IN PATIENTS HOSPITALIZED WITH INFECTION: A MULTI-CENTER COHORT STUDY. Nephrology Dialysis Transplantation, 2018, 33, i475-i475.	0.7	0
855	Centre Effects in Peritoneal Dialysis. , 2018, , .		0
856	FP495PATIENT AND CAREGIVER PRIORITIES FOR OUTCOMES IN PERITONEAL DIALYSIS: AN INTERNATIONAL NOMINAL GROUP STUDY. Nephrology Dialysis Transplantation, 2018, 33, i205-i205.	0.7	0
857	Author reply. Internal Medicine Journal, 2019, 49, 1340-1341.	0.8	0
858	Reply to letter from A Karkar. Peritoneal Dialysis International, 2020, 40, 427-428.	2.3	0
859	Utility of â€œbackâ€œarterioâ€œvenous fistulae in patients on peritoneal dialysis and use of haemodialysis catheters. Internal Medicine Journal, 2020, 51, 1106-1110.	0.8	0
860	NT-proBNP Concentration and Early Cardiac Dysfunction in Patients Receiving Dialysis: A Prospective Cohort Study. CardioRenal Medicine, 2020, 10, 323-332.	1.9	0
861	Variability and trends over time and across centres in haemodialysis weekly duration in Australia and New Zealand. Nephrology, 2021, 26, 153-163.	1.6	0
862	Longer antibiotic durations for treating peritoneal dialysis-associated peritonitis: helpful or harmful?. CKJ: Clinical Kidney Journal, 2021, 14, 735-738.	2.9	0
863	Nephrology in Australia. , 2021, , 701-721.		0
864	FC 082DIET QUALITY, PROTEIN-BOUND URAEMIC TOXINS AND GASTROINTESTINAL MICROBIOME IN CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0

#	ARTICLE	IF	CITATIONS
865	FC 100ASSOCIATION OF SINGLE AND SERIAL MEASURES OF SERUM PHOSPHORUS WITH ADVERSE OUTCOMES IN PATIENTS ON PERITONEAL DIALYSIS: RESULTS FROM THE INTERNATIONAL PDOPPS. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
866	Immunosuppression (IST) Can Be Safely Ceased During Chemotherapy For Post-Transplant Lymphoproliferative Disorders (PTLD) In Renal Transplant Patients. Blood, 2013, 122, 1780-1780.	1.4	0
867	Complications of Peritoneal Dialysis. , 2016, , 121-133.		0
868	Metformin for preventing the progression of chronic kidney disease. The Cochrane Library, 0, , .	2.8	0
869	How to Transition Patients Back From Psychiatric Care to Primary Care: An Access Initiative Protocol Development. Psychiatric Services, 2022, 73, 815-818.	2.0	0
870	Serum Leptin in Peritoneal Dialysis: Is It a Useful Biomarker Following Peritonitis?. Nephro-Urology Monthly, 2011, 4, 333-335.	0.1	0
871	Evaluation of renal function - CARI guidelines. Australian Family Physician, 2007, 36, 46.	0.5	0
872	The incidence of cancer recurrence and new cancer following commencement of dialysis in patients with prior cancers. CKJ: Clinical Kidney Journal, 0, , .	2.9	0
873	Dialysis modality utilization patterns and mortality in older persons initiating dialysis in Australia and New Zealand. Nephrology, 0, , .	1.6	0